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1. The DNA probes used in this study were obtained as inserts in the
plasmid vector pBR 322. They were introduced into the competent cells
E. coli strain HB 101. About five hundred micrograms of recombinant
plasmids can be isolated from one litre of overnight culture of the
transformants.
2. The DNA probes employed in hybridization assays were purified by
electrophoresis and electroelution. As no positive signal was detected
for the plasmid vector in hybridization reconstruction experiment, the
purity of the probe DNA is acceptable.
3. Southern blot hybridization analysis of 28 bronchogenic carcinomas as
well as the respective normal tissue sample of the same patient revealed
the presence of Epstein-Barr virus (EBV) DNA in two (7.14%) of the
tumor specimens. On the contrary, no viral genome was demonstrated
in all the histologically confirmed normal tissues. It was found that
Epstein-Barr virus is, associated with undifferentiated or poorly
differentiated bronchial carcinomas.
4. Human papillomavirus (HPV) DNA related to types 6, 11, 16, and 18
were absent in all the tumor and non-tumor bronchial tissue samples...
Further studies should be conducted in order to clarify the virus tumor
association in question, especially in the squamous histologic type.
65. Southern blot hybridization studies using radiolabelled EBV BamHl-H,-
K, and -W fragments as probes showed the absence of detectable
amounts of Epstein-Barr virus DNA in all the cervical tissue samples
examined.
6. Fourteen cervical squamous cell carcinoma specimens obtained from
Hong Kong Chinese women were analyzed for the presence of human
papillomavirus infection. Eleven (78.6%) tissue samples were found to
harbor HPV DNA sequences related to HPV 16, while 2 others (14.3%)
related to HPV 18. Moreover, no HPV DNA was detected in two normal
cervical epithelial tissues, one cervical intraepithelial neoplasia, as well as
a single case of cervical adenocarcinoma. This finding shows a strong
association between HPV 16 infection and cervical carcinoma in Hong
Kong Chinese women.
7. In the eleven cervical squamous cell carcinomas that probed positively
with HPV 16 DNA, one (9.1%) harbors HPV in episomal form, and six
others (54.5%) in cellular DNA-integrated form. The simultaneous
presence of both episomal and integrated forms was found in the
remaining four tissue specimens (36.4%). It indicates that although HPV
DNA is predominantly integrated into host cellular sequence in cervical
tumors, episomal forms may also exist. The significance of these two
physical states of the viral genomes in cervical carcinogenesis in our
population awaits further study.
78. Southern blot hybridization study of the cervical cancer cell line CC3
showed the presence of HPV 16 related DNA sequences. The altered
viral DNA exists as DNA sequence of similar structure integrated as
single copy or head-to-tail tandem repeats into the host genome at
multiple sites. It was also found that rearrangement or deletion have
occurred in the nude mouse xenografts derived from it.
1CHAPTER 1
Introduction
DNA recombinant technology and gene manipulation have been employed
extensively in production industry. These advances in molecular biology in the
last decade have also provided pathologists with powerful tools in the diagnostic
evaluation of cancer and other pathologic specimens in aid of traditional
techniques such as immunohistochemistry, enzyme histochemistry, electron
microscopy and the use of special stains. Molecular probes may be utilized to
diagnose viral infections as well as to examine the structure and expression of
specific genes in normal, abnormal, as well as neoplastic tissues. In the present
study, DNA probes were prepared from recombinant plasmids for the
investigation of the tumor-virus association of bronchogenic carcinomas and
cervical cancers in Hong Kong Chinese patients through Southern blot
hybridization assay.
Cancer represents a grave threat to human beings. In the world, one
person in five dies of it. In fact, malignant neoplasms have long been the leading
cause of death in Hong Kong. Among which, bronchial cancer shows the highest
prevalence in man (63.6 per 100,000 population). The problem is even worse in
woman, whose world age adjusted incidence rate is 26.8 per 100,000 population,
which is amongst the highest worldwide. As for cancer of the uterine cervix, it
is the third commonest cancer among Hong Kong Chinese women with an
incidence rate of 20.4 per 100,000 population.
2With the advances in molecular technology, it has become evident that
virus may be etiologically associated with a growing number of human cancers.
The recent discovery of the association of Epstein-Barr virus (EBV) and human
papillomaviruses (HPV) with bronchogenic carcinomas is of great interest as
they may represent another carcinogenic factors involved in lung cancer
development. Research should be conducted to evaluate this new idea of
bronchial carcinogenesis in our population. In contrast to carcinomas of lung,
cervical cancer is one of the human cancers in which viruses are thought to have
a major pathogenetic role. The persistence of specific types of HPV genomes
or related DNA sequences in invasive cancer and premalignant lesions of uterine
cervix implies a possible oncogenic role. Attempts were made to demonstrate
the prevalence of these viral DNA sequences by hybridization analysis in the
cervical cancers of Hong Kong Chinese patients.
3CHAPTER 2
Literature Review
2.1 Epstein-Barr Virus (EBV)
A. Classification and morphology
Epstein-Barr virus was discovered during the course of study of Burkitt's
lymphoma (BL) which was the most common pediatric tumor in certain parts
of East Africa [1, 2]. EBV was first recognized electron-microscopically as virus
particles morphologically similar to the herpesvirus group in continuous
lymphoblastoid cell lines established from BL explants in 1964 [3-5]. It was
described as herpes-like or herpes-type virus in the early years before the
designation Epstein-Barr virus was generally used [6, 7].
EBV is classified into the gamma herpesvirus family [8]. All members of
this group are able to infect lymphoid cells in vivo and in vitro, either specific
for T- or. B-lymphocytes. EBV, the only human member of the group, is well
established to have a unique tropism for B-lymphocytes and to induce unlimited
B cell lymphoproliferation [9, 10]. However, recent studies suggested that EBV
not only infects B-lymphocytes but also T-lymphocytes [11-13]. Ubiquitous EBV
infections occur throughout early childhood and early adulthood [14-16]. The
age at which primary infections occur varies with hygienic and socioeconomic
status [17]. It was found that acquisition of the virus occurs at a younger age in
people with lower living standards [18]. The virus is primarily transmitted
4through salivary secretions, which infects the epithelial cells of oropharynx
and/or salivary gland [19-22], as well as peripheral B-lymphocytes [23-25] as
stable accompaniment of the life-long carrier state. It has been shown that at
least 15-20% of normal asymptomatic EBV-seropositive individuals secrete active
virus in their saliva [22, 26-28].
Epstein-Barr virus is morphologically indistinguishable from other members
of the herpes group except their significant size differences. The mature
extracellular EBV particle measures about 150-180 rum across, with an outer
lipoprotein envelope containing a central nucleocapsid with 162 capsomeres [29].
The nucleocapsid is an icosahedron, within which harbors the large DNA
genome- a linear double-stranded DNA consisting of approximately 172 kb
[30].
B. Structure of the viral genome
The virion EBV genome is a large linear double-stranded DNA molecule
of approximately 172 kb with an average- guanine: cytosine base -content of
59.94% [30-32].- 'The genoine consists of unique and tandemly repeated DNA
elements. organized. as TR-UI-IRI-U2-IR2-U3-IR3-U4-IR4-U5-TR (Fig. 2.1)
[33]. TR represents multiple tandem copies of a sequence of 550 bp directly
repeated at both ends of the linear viral DNA [34]. IR1, IR2, and IR4 are
multiple direct tandem repeats of a 3072, 125, and 103 bp DNA sequence
respectively [35, 36]. IR3 designates a sequence of about 700 bp which consists
of direct repeats of three nucleotide triplets: GGG, GCA, and GGA [37]. These
triplets are organized into the hexanucleotide sequence GCAGGA and two
5nonanucleotides GCAGGAGGA and GGGGCAGGA, This internal repeat
codes for a repeating polymer of glycine and alanine [38] contained in one of
the EBV nuclear antigens (EBNA) [39]. As for U1, U2, U3, U4, and U5, they
are unique sequence domains of 10, 3, 59, 40, and 30 kb respectively [30].
Among them, the region U2 varies widely in different EBV isolates [40, 41].
Moreover, there are two partially homologous unique sequences of about 2 kb
(DL and DR) lie adjacent to IR2 and IR4 respectively [33].
Variation exists among the EBV genomes derived from different EBV
isolates in terms of the number of reiterations of tandem repeat elements,
insertions and deletions of DNA sequences, as well as polymorphism of specific
restriction endonuclease sites [42-45]. The DNA probes employed in this study
was derived from B95-8 virion DNA in which the restriction enzyme recognition
sites had been determined [46]. A diagrammatic representation of the EcoRI
and BamHI restriction map of the DNA sequence of B95-8, an infectious
mononucleosis-derived isolate of EBV, was shown in Fig. '2.2 [47].
In latently infected -cell s, mostly harbor multiple copies of EBV DNA.
genome per cell-148-50], the virus usually persists in the form of covalently closed
circular episomes (Fig. 2.3) [51, 52]. However, EBV may also persist as
integrated sequence in the host genome [53, 54] or as both integrated and
episomal DNA [30]. The episome, suggested to have multiple replication origins
[55], is formed by covalently linking the terminal repeats (TR) located at the
opposite ends of the EBV DNA [33]. Out of the 80-100 genes in EBV [56],
only a few is expressed in the latently infected cells [57-59]. To date, the best
characterized latent gene products are EBNA 1, EBNA 2, EBNA 3, and LMP,
6which will be discussed in the next section. Integration of the viral DNA into
the host cell genome may probably accompanied by deletion of the viral and/or
cellular DNA sequence [30]. However, the significance of EBV integration into
host cellular sequence in determining its growth transforming and oncogenic
properties is still not clear.
C. The virus-determined antigens
Epstein-Barr virus was originally discovered as a herpes-like virus in
lymphoblastoid cell lines established from BL explants [5]. In addition to
significant size difference, EBV is distinct from other herpesviruses on a
serological basis [60].
There are five major groups of EBV antigens, namely, EBV nuclear
antigens (EBNA) lymphocyte-determined membrane antigens (LYDMA)
EBV-induced membrane antigens (EA) EBV-associated membrane antigens
(MA) and viral capsid antigens (VCA) [61]. Based on the stage of the virus
lytic cycle, these serologically defined antigens can be grouped into three
categories: transforming antigens, early antigens, and late antigens [60].
. Transforming antigens (EBNA LYDMA) are expressed in all EBV-
infected cells studied so far, thus can be used as markers for the presence of
EBV. As for early antigens (EA), their expression is insensitive to DNA
synthesis inhibitors [62]. It is generally accepted that when EA is produced in
EBV-infected cells, the latter is doomed to complete the lytic cycle, release
infectious viruses, and die [63]. MA and VCA are classified as late antigens,
7their synthesis is related to the viral DNA replication takes place in the infected
cells.
EBNA is invariably expressed in all EBV genome-carrying cells, including
Burkitt's lymphoma, nasopharyngeal carcinoma biopsies, and peripheral blood
lymphocytes isolated from the blood of patients with. infectious mononucleosis
[64-66]. Its synthesis is the earliest event in the process of lymphocyte
immortalization [67]. EBNA can be readily detected in the nuclei of EBV-
infected cells by anti-complement immunofluorescence (ACIF) assay [68]. Recent
analysis revealed that EBNA is a family of at least five proteins, designated as
EBNA1 to EBNA 5, with variable sizes in different cell lines.
EBNA 1 is a sequence-specific DNA-binding protein with high affinity to
single-stranded DNA [69]. It specifically binds to the origin of EBV DNA
replication (ori-P) localized in the BamHI fragment C of the viral genome and
supports the replication of plasmids containing ori-P sequences [70-72]. It is
encoded by the BamHI fragment K rightward reading frame 1 (BKRF1) [38, 39]
together with an axon from BamHI fragment E [73]. Its possible functions
include the maintenance of viral latency and episomal state of EBV genome [70,
72, 74], as well as the initiation and/or maintenance of transformation [75].
Like EBNA 1, EBNA 2 is localized to the nucleus of EBV-infected cells
and is encoded by the BamHI fragment Y rightward reading frame 1 (BYRF1)
as well as the BamHI H and W regions of EBV genome [76-78]. Transcription
of EBNA 2 gene was initiated in the BamHI W fragment, the transcript was
spliced, and the entire EBNA 2 protein was encoded within the continuous long
8open reading frame in the BamHI Y and H fragments [79]. EBNA 2 was
thought to be involved in the initiation of virus-induced B-cell transformation
[80, 81], and plays a continuous role in the determination of cellular growth
phenotype [82].
EBNA 3 is a nuclear protein expressed in latently infected growth-
transformed cells. This protein, together with other EBV proteins produced
during latent infection, are likely to play a role in the maintenance of persistent
latent viral infection as well as gene regulation or growth transformation [83].
As for EBNA 4, like EBNA 1, 2, and 3, bounds to double- and single-stranded
DNA in vitro [84]. It was suggested that this nuclear protein, is encoded by the
BERF1-related open reading frames, BERF- 2b and BERF 4 [85]. EBNA 5 is
encoded partly by BERF-2b and BERF 4 [85], as well as partly by exons from
the BamHI W, Y, and H restriction fragments of the EBV genome [86]. Their
exact function is not yet clear.
LYDMA is present on the surface of EBV-transformed cells. This protein
has been known for years as the target structure of EBV-specific, cell-mediated
immunity. However- little is known about its nature. It was suggested that a
membrane protein, known as the latent membrane-associated protein (LMP),
encoded by EcoRI fragment Dh«, is probably identical to LYDMA [87, 88]. The
possible functions of LYDMA include the stimulation of cell-mediated immunity
against EBV-transformed cells, as well as the maintenance of the transformed
state [60].
9The expression of early antigens is independent of viral DNA synthesis
[89]. The cells that produce EA are committed to die and release infectious
viruses [63]. Early antigens can be resolved into two components. The diffuse
form, EA-D, is present in both the nucleus and cytoplasm while the restricted
form, EA-R, is localize in the cytoplasm [90]. Individuals with EBV-associated
BL show unusually high antibody titer to EA-R, in contrast to NPC patients,
whose sera have antibody predominantly against the diffuse component. The
biological role plays by the EBV early antigens is not yet clear. However, their
synthesis marks the switch from latent state to viral lytic cycle. Bayliss and Wolf
reported that an EBV early protein could induce EBV-mediated cell fusion [91],
which may represent the route through which EBV enters the cells without viral
receptors [91, 92].
Membrane antigen complex is composed of both early and late
components, EMA and LMA, which are synthesized late in the virus replication
cycle. Cytotoxic immune response mediated .by antibody-dependent cellular
cytotoxicity (ADCC) to EMA on cells in early stages of lytic cycle would destroy
the latter before virus particles were released [93]. Other than that, EMA may
also serve as a target -for natural killer (NK) cells [94]. As for late membrane
antigens, they are found both in the virion envelope as well as on the cytoplasmic
membrane of cells undergoing viral lytic cycle [29, 61]. The major function of
membrane antigens on the viral envelope is the binding and adsorption of the
virion to the receptors on target B-lymphocytes [60].
Viral capsid antigens were detected in virus-producing cell lines. Their
expression is inhibited by viral DNA synthesis inhibitors, thus indicating that
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they are late viral antigens [95]. The major polypeptides composing the VCA
complex include proteins with molecular weights of 125, 152, and 160 kilodaltons.
The 160 kDa non-glycosylated protein is mainly located in the nuclei of infected
cells [96], which was suggested to be the major protein composing the viral
capsid. On the contrary, the 125 kDa glycosylated protein was detected both in
the cytoplasm and nuclei [97], which appears to be the major immunogen
following primary EBV infection [98].
The study of antibody profiles to VCA, EA and EBNA is useful in the
serodiagnosis of EBV infection. Primary infection is suggested if the serum of
a patient shows no anti-EBNA antibodies, but the presence of anti-VCA (IgM
and IgG) and transient anti-EA antibodies. In contrast, established latent
infection is suggested by the stable levels of anti-VCA (IgG) and EBNA
antibodies in the absence of anti-EA antibodies. Moreover, reactivation of EBV
can be readily diagnosed by the recurrent elevation of anti-EA antibodies [99].
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2,2 Human Papillomaviruses (HPV)
A. Classification and morphology
Papillomaviruses are a group of small DNA viruses, which are strictly
epitheliotropic and induce a variety of proliferative squamous epithelial tumors
or fibroepithelial tumors in their natural hosts. They are widely distributed in
nature and infect many higher vertebrate species ranging from birds to human
[100]. Although the viral origin of human warts had been demonstrated by
Ciuffo in 1907 through the observation of their cell-free filtrate transmission
[101], our knowledge of the biological and pathogenic characteristics of this
important group of tumor viruses remained rudimentary until the recent
advances in biotechnology. Progress was mainly hampered by the lack of a
suitable tissue culture system for the in vitro propagation of these viruses. It has
been found that replication of papillomaviruses appears to be highly dependent
on the differentiation of keratinocytes [102]. The development of biotechnology
enables sufficient quantities of viral genetic materials to be obtained through the
molecular cloning of papillomavirus genomic DNA isolated from clinical
specimens. To date., there is still no reproducible in vitro system has been
developed that supports papillomavirus replication.
Papillomaviruses are about 55 nm in diameter as determined by electron
microscopy [103]. The viral genome is confined in a naked icosahedral capsid
with 72 capsomeres [104]. Based on the similar appearance of the
papillomavirus virions and those of the simian virus 40 (SV 40) and the murine
polyomavirus, papillomaviruses were grouped together with. them to form the
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family Papovaviridae consisting of two genera, Papillomavirus and Polyomavirus
[105]. However, recent studies revealed that the viruses are genetically and
biologically unrelated and should be classified into different families of viruses
[100].
Unlike some human viruses, such as adenoviruses, it is impossible to type
papillomaviruses by serologic methods due to the absence of developed type-
specific antisera. As a consequence, papillomaviruses are at present classified
first according to their species of origin, and then the viruses from a given•.
species are considered as types and subtypes based on the degree of relatedness
of their nucleotide sequences [106]. By definition, papillomaviruses are
considered as independent types if there is less than 50% cross-hybridization
with each of the other defined types when assayed under stringent hybridization
conditions. If the extent of DNA cross-hybridization between two isolates
exceeds 50% but is obviously incomplete, they are defined as subtypes.
Moreover, viruses are called variants if the DNA sequences of two isolates differ
only in a number of restriction enzyme cleavage sites. With this classification
scheme, there are approximately 60 characterized human pathogenic genotypes
[107].'
Studies on the nucleotide sequences of papillomaviruses indicates that the
extent of cross-hybridization does not reflect the actual degree of homology at
the nucleotide sequence level. Viruses which show no cross-hybridization at all
under stringent hybridization conditions may still have more than 50% sequence
homology as determined by sequence analysis [108]. Hence, it has been claimed
that the characterization of human papillomaviruses by DNA hybridization may
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not be sufficient, as it could exaggerate the number of viral types and presents
no prognostic significance [106, 109]. It was suggested that HPV should be
reclassified in the future based upon their serologic properties, pathological
features, as well as oncogenic potentials. The clinical association of some
characterized HPVs is listed in Table 2.1.
B. Organization of the viral genome
The genome of papillomaviruses is composed of a supercoiled covalently
closed circular double-stranded DNA molecule with a molecular weight of
approximately 5000 kilodaltons [110, 111] representing about 8000 base pairs
[112]. The average guanine-cytosine base content is about 41% [113]. Although
the viral genomes of human and animal papillomaviruses exhibit little sequence
homology [114, 115], DNA sequence analysis indicates that the general genomic
organization of each of the papillomaviruses is strikingly similar [116]. To date,
the most extensively studied papillomavirus is bovine papillomavirus type 1 (BPV
1), which has served as a model for unraveling the molecular biology and
genetics of this group of small DNA viruses.
Papillomaviruses have a very compact genome. There are few non-coding
nucleotide sequences interspersed among the coding regions that constitutes
about 90% of most papillomavirus genomes [116]. All the major open reading
frames (ORFs) are located on the same DNA strand [117, 118]. As no tissue
culture system is available for the in vitro propagation of papillomaviruses, it is
impossible to classify the viral genes into "early genes" and "late genes" according
to the viral replication cycle. Nevertheless, on the assumption that the "early
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genes are synonymous with the genes which are expressed in transformed cells,
the ORFs of papillomavirus genome can be functionally divided into two coding
regions: the early (E) region and the late (L) region [116].
Bovine papillomavirus type 1 is associated with cutaneous fibropapillomas
in cattle and is able to induce fibroblastic tumors in a variety of foreign hosts,
including horses, hamsters, and rabbits [119]. Eight ORFs in the E region have
been identified on-the coding strand of BPV 1 genome, which are designated
El to E8 (Fig. 2.4) [120]. Five of them, namely, El, E2, E4, E6, and E7 appear
to have equivalent analogs in all papillomavirus genomes sequenced so far [116].
Upstream to these ORFs is a non-coding region (ncr) of 1 kb in length that
contains transcriptional control elements [121], a DNase I-hypersensitive site
[122], the initiation site for plasmid DNA replication in rodent cells [123], and
a plasmid maintenance sequence [124]. This region of the viral DNA, together
with the ORFs in the E region, have been shown to be sufficient for cellular
transformation [125, 126], as well as for stable.,plasmid maintenance [127]. The
late region, which covers about 3 kb in the BPV 1 genome, is located
downstream to the E region. Two large open reading frames, designated Ll
and 1-2, are found to- be present in all the sequenced papillomavirus genomes.
It is believed that they code for structural proteins present in the papillomavirus
capsid [128]. The possible functions of the ORFs are listed in Table 2.2.
Deletion mutagenesis studies and cDNA cloning experiments have shown
that the gene products encoded by ORFs E5, E6, E6/E7, and possibly E2 of.
the BPV 1 genome are involved in cellular transformation [121, 124, 129, 130].
Moreover, it was demonstrated that the E2 ORF encodes -a diffusible factor
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required for the trans-activation of an enhancer element located in the non-
coding region of the BPV 1 DNA, which leads to the expression of the early
genes [130, 131]. Although serologic studies on papillomaviruses are hampered
by the failure in propagating the viruses in tissue culture systems, immunologic
relatedness of papillomaviruses can still be implied by immunocytochemical
studies. The antiserum prepared by immunization of rabbits with detergent or
alkali-disrupted virions was cross-reactive with all papillomaviruses, whereas the
antiserum raised against intact whole virions was type-specific [132, 133]. It
indicates that papillomaviruses possess a common internal antigen, most
probably a structural component of the virion, which is not readily accessible
to the immune system. It is consistent with the findings obtained from DNA
sequence analysis and heteroduplex studies that El and L1 ORFs are highly
conserved, followed by E2 and L2, among the viruses studied so far [108, 116,
134].
16
2.3 Anatomy and Histology of the Lungs
The lungs are the essential organs of respiration protected by the thoracic
cage. They are confined in their own pleural sac on each side of the
mediastinum in the thoracic cavity, and are attached to the heart and trachea by
their roots and the pulmonary ligaments. In human, the left lung is divided into
superior and inferior lobes by a long deep oblique fissure, whereas the right lung
is divided into superior, middle, and inferior lobes by oblique and horizontal
fissures. However, about 8% of people have an extra middle lobe in the left
lung separated by a second fissure [135].
The essential tissue for gaseous exchange in the lungs is an attenuated
squamous epithelium that forms the alveolar wall, which intervenes between the
capillaries of the pulmonary circulation and the air contained in the alveoli. Air
from the external atmosphere enters the alveoli of the lungs through a branching
network of tubes at the hilum of the lung, known as tracheobronchial tree [135].
It begins with the trachea, which is the distal continuation of the larynx, and
descends through the neck into the thorax where it bifurcates into the left and
right principal bronchi. From each of these primary bronchi originates the
secondary or lobar bronchi, and each of the latter supplies air to a lobe of the
lung. Each lobar bronchus then further divides into segmental bronchi which
conduct air to the ten bronchopulmonary segments in each lung. Beyond the
segmental bronchi, approximately ten more generations of bronchi are produced.
The most distal of them are about 1 mm in diameter. The next two to three
generations of airways are called bronchioles. The most distal of them, terminal
bronchioles, conduct inspired air to the respiratory unit of the lungs, known as
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acinus or lobule. Within the acinus, each terminal bronchiole branches into
several respiratory bronchioles, they in turn lead to the alveolar ducts which
immediately branch into the alveolar sacs where gaseous exchange takes place.
It has been found that bronchogenic carcinomas arise most often at or near the
hilus of the lung, and about three-fourths of the lesions originate from the first-,
second-, and third-order bronchi [136].
The trachea and bronchi are lined by pseudo-stratified, ciliated, tall,
columnar epithelial cells. Numerous submucosal mucus-secreting glands are
dispersed throughout their walls. Within the tracheobronchial epithelium, five
cell types are identified, namely, ciliated columnar cells, mucus-secreting goblet
cells, basal cells, columnar brush cells, and bronchial Kultschitzky cells [137].
The mucus moistens the inspired air and traps the foreign materials such as dust
and particulate matter, which are eventually removed by the beating action of
cilia. As for the brush cells, they have been found in close association with
nerve fibers and are thought to be related to a sensory function [137]. The
bronchial Kultschitzky cells are found in the basal layer of bronchial epithelium
and exhibit neurosecretory-type granules [138, 139], and contains serotonin,
calcitonin, and bombesih [136]. The function of these granular cells is not well
understood. As they have long dendritic-like cytoplasmic processes insinuated
between the bronchial epithelial cells, they might be a type of sensory nerve
ending [138]. It was suggested that Kultschitzky cells are the precursors of the
carcinoid tumors and small cell carcinomas of the lung [136].
In small bronchi, the epithelium is similar to the tracheobronchial
epithelium, but with shorter columnar cells and less goblet cells. As for the
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larger bronchioles, the epithelial lining becomes ciliated columnar, with low
columnar cells and few goblet cells. Just before reaching the acini, the
bronchioles are called terminal bronchioles as described before. They have
numerous ciliated cells and Clara cells, as well as some brush cells and bronchial
Kultschitzky cells. The Clara cells are non-ciliated and secrete surface-active
agents [138]. No goblet cell is present in the terminal bronchioles of healthy
lungs.
Respiratory bronchiole is the first part of the respiratory tract where
gaseous exchange takes place. The walls of the larger respiratory bronchioles
are interrupted by alveoli and consist of cuboidal epithelium with some ciliated
cells and Clara cells. Further along these bronchioles towards the alveoli,
ciliated cells are no longer present and the Clara cells are frequently found
interspersed among the low cuboidal or squamous epithelial cells.
The alveolar epithelium is the principal .site of gaseous exchange. It is
perforated by the pores of Kohn which allow communication between adjacent
alveoli. Two types of epithelial cells are found in. the alveolar wall: flattened
plate-like type I pneumonocytes,'which covers about 95% of the alveolar surface
and the round/cuboidal granular type II pneumonocytes that are chiefly located
at septal junctions. Apart from them, alveolar macrophages are also found in
alveoli which are usually filled with carbon particles and other phagocytosed
materials. Type II pneumonocytes are the source of pulmonary surfactant which
reduces the surface tension of alveolar lining to ensure the normal expansion
of alveoli [140]. Moreover, they also respond rapidly to injury by cell division
and replace the type I pneumonocytes [138]. It is believed that any respiratory




Malignant neoplasms are now the leading cause of death in Hong Kong,
followed by cardiovascular diseases and cerebrovascular diseases [141]. Mortality
from lung cancer in both males and females increased rapidly during the past
two decades [142]. In 1987, the mortality rates of males and females in Hong
Kong were 55.7 and 31.4 per 100,000 population respectively. The age-
standardized incidence rate of bronchial cancer in Hong Kong women, where
98% of the population is Chinese [143], is remarkable, which was found to be
the highest worldwide in 1981, followed by Scotland and Iceland [144]. In 1984,
the world age adjusted incidence rate was 26.8 per 100,000 population [145]. On
the contrary, the incidence rate of males (63.6 per 100,000 population in 1984
[145]) is not particularly high as compared with other occidental countries [144].
This results in the strikingly -low male to female ratio, which was about 2.4:1 in
1984. A high incidence or mortality rate of bronchial cancer is also noted among
the Chinese women (especially. Cantonese) 'in other parts of the world, including
China [146], Singapore [147, 148], United States [149], and Hawaii [150].
In Hong Kong, bronchogenic carcinomas occur most often between ages
45 and 70, with a peak incidence in the sixth or seventh decade [141, 151]. The
predominant histological type of lung cancer in male patients was found to be
squamous cell carcinoma followed by adenocarcinoma whereas in females, the
reverse was observed [152, 153]. Cigarette smoking is a major carcinogenic
factor involved in the development of squamous cell carcinoma and small cell
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carcinoma, which are usually centrally located, in both of our male and female
patients. However, adenocarcinoma usually occurs in non-smokers, especially
in women. Adenocarcinoma in Hong Kong female patients is predominantly
centrally located [152-154] which contrasts markedly with that observed in other
countries, such as Japan [155] and United States [156], where most of the cases
reported are of peripheral type. The frequent occurrence of adenocarcinomas
in Hong Kong women suggests that inhaled carcinogens might be in operative
in the histogenesis of this tumor, which may come from kerosene stoves, incense
smoke, passive cigarette smoking, or other unknown sources [152, 153].
B. Pathology and histologic classification
Lung cancer is the most frequently diagnosed malignant neoplasm
throughout the world. The principal histologic classification was formulated by
the World Health Organization (WHO) [157]. It classifies bronchogenic
carcinomas into four main histopathologic types: squamous cell carcinoma,
adenocarcinoma,' small cell carcinoma (SCLC), and large cell carcinoma that
collectively account for about.95% of the cases diagnosed [156, 158]. However,
clinicians. have been predominantly concerned with the division of lung cancers
in.SCLC and non-SCLC types, which is based on the relative sensitivity of SCLC
to cytotoxic therapy, its frequency of metastatic spread, and distinct biological
features [159]. Nevertheless, recent studies suggest that subtyping of the non-
SCLC type presents an emerging clinical role [160].
From a review of 480 Hong Kong patients with bronchogenic carcinomas
[152], it was found that all patients with SCLC were- symptomatic on
21
presentation, while some non-SCLC patients were asymptomatic and came to
medication because of abnormality detected in routine chest roentgenograph.
Patients with different histologic types of bronchogenic carcinomas have varied
clinical features, in which anorexia and malaise, cough, dyspnea, occurrence of
supraclavicular/cervical nodes, chest pain/discomfort, and hemoptysis are the
most common symptoms encountered in all of the patients.
The WHO classification [157] includes tumors and tumor-like lesions of
the pulmonary parenchyma, the bronchi, and the pleura. The definitions of
tumor types are based entirely on tumor cell appearance as seen by light
microscopy, and made no emphasis on histogenesis. As a common rule, the
tumors are classified by the best differentiated region of the tissue and are
graded to different degrees of differentiation by its most poorly differentiated
portion [144].
(a) Squamous cell carcinoma
Squamous cell carcinoma is closely associated with cigarette smoking and
predominantly occurs centrally and arises from the areas of chronically damaged
bronchial epithelium in principal, lobar, or segmental bronchi. However, some
of them may arise in small bronchi in peripheral lung tissue. Squamous cell
carcinoma is thought to develop from a progressive dysplasia of metaplastic
squamous epithelium eventually leading to carcinoma -in situ and invasive
carcinoma [156, 161, 162]. It is uncommon for squamous cell carcinomas to
metastasize early instead, they tend to invade locally and block the bronchial
lumen, causing obstructive diseases such as postobstructive- pneumonitis and
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hemoptysis. Moreover, the tumor may also invade the underlying lamina propria
and peripheral lung tissue, producing signs of impingement on adjacent
structures such as the mediastinum, chest wall, or diaphragm [163]. Massive
necrosis and cavitation are as well common in this histologic type.
Most squamous cell carcinomas show a significant degree of histologic
heterogeneity. The histologic diagnosis is based on the identification of visible
keratinization and/or intercellular bridges [157]. Ultrastructurally, the cancer
cells show prominent desmosomes and bundles of intermediate filaments that
frequently terminate on desmosomes [144]. Occasionally, squamous cell
carcinomas develop areas of spindle cells leading to a biphasic appearance of
the tumor. A striking host cellular response can also be demonstrated, which
is characterized by a prominent lymphoid stromal infiltration.
(b) Adenocarcinoma
Morphologically, adenocarcinoma of the lung is the most heterogeneous
type of bronchogenic carcinomas. It is the most common type of lung cancer
associated with non-smokers [164], and usually arises in the periphery of the
lung from bronchial glands or peripheral mucosa, as well as from areas of
scarring [162]. Recent studies suggested that the scarring represents a
desmoplastic reaction to the tumor rather than the tumor arising from it [165-
167]. Patients with adenocarcinomas are often asymptomatic at the time of
diagnosis. These tumors tend to metastasize early, with predilection for the
central nervous system and adrenal glands [168]. However, adenocarcinomas
found in the lungs may also be metastases from adenocarcinomas in other sites
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such as the gastro-intestinal tract, the ovaries or pancreas [157].
The histologic criteria for diagnosing adenocarcinoma include gland
formation by the tumor cells or the presence of intracellular mucin. According
to the WHO guidelines, adenocarcinoma are classified histologically into four
subtypes: (1) acinar adenocarcinomas in which the tumor cells form acini and
tubules (glandular structures) (2) papillary adenocarcinoma in which there is a
predominance of papillary structures (3) bronchiolo-alveolar carcinoma, in
which columnar cells grow upon 'the walls of pre-existing alveoli and (4) solid
carcinoma with mucus formation, in which mucus-containing vacuoles are found
within the tumor cells with large nuclei and abundant cytoplasm. Moreover, no
acini, tubules, and papillae are present.
(c) Small cell carcinoma (SCLC)
Small cell carcinoma, which is also frequently called oat cell carcinoma, or
neuroendocrine carcinoma of small cell type, is the most aggressive form of lung
cancer. SCLC rarely occurs in non-smokers [169] and mostly begins as a central
lesion with rapid spread to submucosal sites and then regional lymph nodes,
hence it is unusual for SCLC to be detected as preclinical localized lesions by
sputum cytology or bronchoscopy [168]. Some pathologists believed that SCLC,
like squamous cell carcinoma, derived from bronchial epithelium [170], while
others claimed that SCLC, together with carcinoids, arise from pulmonary
Kultschitzky cells [171]. It is now clear that SCLC has distinguishing clinical and
biological properties. Of all the histologic types of lung cancer, SCLC is the
most sensitive to a wide range of chemotherapeutic agents and has unique
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neuroendocrine properties. The polypeptide hormones produced by the tumor
cells are responsible to a variety of paraneoplastic syndromes [172]. The most
common syndromes are Cushing's syndrome (due to ACTH production),
syndrome of inappropriate ADH secretion (SIADH), and myasthenic syndrome.
According to the WHO classification scheme, this neoplasm is divided into
three categories: (1) oat cell carcinoma, which is characterized by the presence
of small round uniform cells approximately 1.5 to 3 folds larger than
lymphocytes, with dense round or oval nuclei and sparse cytoplasm (2) small
cell carcinoma, intermediate cell type, which is diagnosed as being composed
of small polygonal or fusiform cells less regular in appearance than the oat cells,
but with similar nuclear characteristics and more cytoplasm (3) combined oat
cell carcinoma, characterized by the presence of a definite component of oat
cell carcinoma with squamous cell carcinoma and/or adenocarcinoma [157].
(d) Large cell carcinoma
Large cell carcinoma usually presents as a large, bulky peripheral mass.
It is defined by the WHO classification of lung neoplasms as a malignant
epithelial tumor in which the tumor cells have large nuclei, prominent nucleoli,
abundant cytoplasm, and usually well-defined cell borders, without the
characteristic features of the other three histologic types [157]. These diagnostic
criteria are somewhat of a 'waste-basket' diagnosis [173]. Ultrastructural studies
revealed that the majority of light microscopically diagnosed large cell carcinoma
shows evidence of glandular or squamous differentiation, as well as features of
other types of neoplasms [144].
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According to the WHO guidelines, large cell carcinoma has two variants:
giant cell carcinoma and clear cell carcinoma [157]. Giant cell carcinoma is
composed of a prominent component of highly pleomorphic, frequently
multinucleated giant cells that usually contain neutrophil leukocytes in their
cytoplasm. Clear cell carcinoma is rare. It is characterized as being composed
of elements with clear or foamy cytoplasm without mucin.
All lung tumors show histologic heterogeneity. They may be bicomponent
or multicomponent [174, 175]. Based primarily on this observation, some.
pathologists believe that various histologic types of bronchogenic carcinomas
originate from small cell carcinoma which changes to an intermediate form, and
eventually develops into large cell carcinoma [176]. The latter may then
differentiate into squamous cell carcinoma and adenocarcinoma.
C. Etiological factors
The striking increase in lung cancer incidence throughout the world has
drawn much effort on the study of its etiology. To-date, cigarette smoking is the
most important preventable'cause of lung cancer [177, 178]. However, since only
10% of heavy cigarette smokers develop carcinoma of the lung, the disease is
probably of multifactorial etiology [144].
The evidence indicating smoking as a major etiological factor comes from
the collection of three kinds of evidence: statistical, clinical, and experimental
[179]. The statistical evidence is the most compelling. About 80 to 90% of
bronchogenic carcinomas may be directly related to active cigarette smoking,
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and the risk is increased with the amount of cigarettes smoked per day, the
duration of smoking habit, depth of inhalation, onset of smoking at earlier age,
as well as the tar and nicotine content of cigarettes [177, 180]. Moreover, the
relative risk of ex-smokers decreases with the number of years since smoking
cessation [181]. As compared with non-smokers, smokers have a 10-25 fold
increased risk of developing lung cancer.
The clinical evidence has been obtained mainly from the study of changes
in the respiratory epithelial lining in smokers and non-smokers. Several types.
of histological changes in bronchial epithelium occurred far more frequently in
the former, these include basal cell hyperplasia, loss of bronchial cilia in some
areas of the respiratory tract, and the occurrence of cells with atypical nuclei
[161]. The presence of atypical cells were proposed to be the first definite step
leading to carcinoma in situ and finally to invasive carcinoma. Moreover, it was
found that the number of cells with nuclear abnormalities diminished
progressively upon cessation of cigarette smoking [182]. As for the experimental
evidence, it comes from the attempts to induce tumors in experimental animals
by the extracts of tobacco smoke. Analysis of the-latter revealed that it contains
..carcinogens, mutagens, and tumor promoters [178].
The potential harmful effects of passive smoking remains controversial.
Some studies demonstrated that non-smokers exposed to passive smoking have
an increased risk of developing lung cancer [183-185], while others denied it
[186, 187]. This controversy is as well observed in Hong Kong. From the studies.
carried out in 1979 and 1983, both authors claimed that no significant association
was found [154, 188]. However, in a more recent study, it was found that passive
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smoking is a risk factor for lung cancer, especially adenocarcinoma, in Hong
Kong female non-smokers [189]. Nevertheless, the analysis of side-stream smoke
of cigarettes revealed that it has higher concentrations of nitrosamine,
benzopyrene, and naphthalene as compared with main-stream smoke [190].
Moreover, there is no doubt that passive smokers do absorb nicotine and other
harmful substances [191].
There are several other factors important in the development of lung
cancer. Most of them are occupation-related factors or air pollutants. Radiation,
either direct exposure or, inhalation of radioactive dust particles, is one of the
major industrial hazard. From extensive studies, increased risk was also found
among individuals who work with asbestos, arsenic, nickel, chromates, beryllium,
mustard gas and halogenated ethers [192]. Among them, asbestos has been
universally recognized as a potent pulmonary carcinogen. Apart from these
occupational exposure, increased risk in lung cancer incidence coincides with
industrialization. Many- atmospheric pollutants have been identified, their
content varies among different cities and countries [192]. However, the
popularity of cigarette smoking in urban areas makes* the association difficult
to be clarified.
The importance of genetic factors in the carcinogenesis of lung cancer
has also been investigated. To date, no convincing evidence has been obtained.
Instead, it was found that environmental factors are of greater importance than
hereditary factors or racial susceptibility. Pulmonary scarring is as well suggested
to be a common area from which lung cancer, especially adenocarcinoma,
develops. However, recent studies indicate that it may, be a desmoplastic
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.reaction to the tumor [165-167]. An inverse association was also demonstrated
between vitamin A consumption and lung cancer risk [193]. It is believed that
it may be due to the anticarcinogenic effect of betacarotene, which is the main
dietary precursor of vitamin A. Finally, some studies suggested that two viruses,
namely Epstein-Barr virus and human papillomavirus, may play a role on the
carcinogenesis of bronchogenic carcinomas. It will be discussed later.
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2.5 Anatomy and Histology of Uterine Cervix
The cervix is the most inferior portion of the uterus, protruding into the
upper vagina. The latter fuses circumferentially around the distal part of the
cervix, dividing it into vaginal and supravaginal parts [194]. The vaginal portion
(portio vaginalis, or exocervix) communicates with the vagina via the uterine
ostium, or known as the external os, which is interconnected with the isthmus
(internal os), the narrow zone of transition between the body and cervix of the
uterus, by the cervical canal [195]. The uterine cervix is held in position by the
transverse cervical ligaments which extend from the cervix and lateral fornices
of the vagina to the lateral walls of the pelvis as well as by the uterosacral
ligaments that connects the sides of the cervix to the sacrum.
The exposed or vaginal portion of the cervix is generally lined by a
stratified squamous non-keratinizing epithelium, which more or less extends up
to the central dimple that comprises the external os. Three zones can be
identified in the mature cervical squamous epithelium: (1) the basal or germinal
layer that responsible for the continuous renewal of epithelial cells (2) the mid-
zone, which is the dominant portion of the epithelium and (3) the superficial
zone that contains the most mature cell population. The endocervix is lined by
simple columnar, mucus-secreting epithelium, which extends down into the
underlying stroma to form deep, uncrossed, cleft-like infoldings known as
endocervical glands [195]. The tall columnar cells characteristically have basally
situated nuclei and uniform, finely granular cytoplasm filled with mucinous
droplets. The middle coat of the cervix consists mostly of fibrous tissue, thus
making it more firm and rigid than the body of the uterus.
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Much attention has been drawn to the squamocolumnar junction of the
cervix, called transformation or transition zone, where most cervical carcinomas
arise. It is the border between the stratified squamous epithelium of the cervical
portio and the mucus-secreting columnar epithelium of the endocervical canal.
In most of the women during the reproductive period, the endocervical
epithelium migrates downward from the external os to the portio, this
phenomenon is known as cervical ectropion or ectopy. From the ectropions, two
mechanisms involved in the genesis of the squamous epithelium of
transformation zone have been proposed [195]. The first mechanism is
squamous epithelialization through the direct ingrowth of the native portio
epithelium adjacent to the columnar epithelium. The second mechanism
involves the proliferation of the undifferentiated small cuboidal subcolumnar
reserve cells of the endocervical columnar ectropion, which gradually
differentiate into fully mature squamous epithelium. This process is most




Cancer of the female lower genital tract including vulva, vagina, and cervix,
remains one of the most important categories of neoplastic disease. Among
them, cancer of the cervix is the most common one [196]. The geographic
distribution of cervical cancer is varied in different parts of the world. In many
developed countries, the incidence of cervical cancer is overshadowed by other
neoplastic diseases as a cause of death. In contrast, by taking the developing
countries as a whole, cancer of the cervix is still the major cause of death from
malignant diseases in woman, especially in middle age. The reduced mortality
from the disease in developed countries may be due to the increase in screening
for cervical cancer, which leads to early discovery and close follow-up of the
lesions [196].
In Hong Kong, cancer of the cervix is ranked third in incidence and
seventh in mortality among the neoplasms in females. The mortality rate in.1987
was 4.7 per 100,000 population [141], while the world age adjusted incidence rate
in 1984 was 20.4 per 100,000 population [145]. The disease occurs most often
in women between ages 45 and 60, with a peak incidence in the range of 50 to
54 in age [141].
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B.. Pathology and histologic classification
(a) Cervical intraepithelial neoplasia (CIN)
Cervical carcinoma is believed to arise from precursor lesions [197, 198].
In the majority, of cases, the invasive disease is the end stage of a continuum of
progressively more atypical changes. The classic terminology divides the
precursor lesions into dysplasia and carcinoma in situ (CIS). The definition of
dysplasia, as proposed by the World Health Organization, is a lesion in which
part of the thickness of the epithelium is replaced by cells showing varying
degrees of atypia while CIS is defined as a lesion in which all or most of the
epithelium shows the cellular features of carcinoma [199].
Over the last two decades, all the information obtained from light
microscopy, electron-microscopy [200], autoradiography [201], tissue culture
[202], and cytogenetics [203] has indicated that the cells of dysplasia and CIS
are virtually identical and could be defined as monoclonal proliferations of
abnormal epithelial cells with an aneuploid nuclear DNA content [204]. Hence,
a unified concept of cervical cancer precursor lesions was developed and termed
cervical intraepithelial neoplasia (CIN). It describes a spectrum of histologic
changes that share a common etiology, biology, and natural history. The term
CIN implies that invasive carcinoma may arise from it if left untreated. In the
United States, it was found that the mean age of patients with severe stage of
CIN is 15 years younger than that of the patients with invasive disease [205].
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Cervical intraepithelial neoplasia is usually divided into three grades: CIN
1, CIN 2, and CIN 3 based on the proportion of the epithelium occupied by the
undifferentiated cells. CIN 1 corresponds to mild dysplasia in which less than
one-third of the full thickness of epithelium is involved CIN 2 corresponds to
moderate dysplasia which represents one-third to two-thirds involvement and
CIN 3 includes both severe dysplasia and carcinoma in situ of the dysplasia-CIS
scheme terminology, in which two-thirds to full thickness of the cervical
epithelium is involved (Fig. 2.5) [206].
It is quite probable that the atypia starts as CIN 1, which progresses to
CIN 2, then CIN 3, and finally to invasive carcinoma. However, lesions of
various degrees of abnormality (all grades of CIN) may also progress directly to
invasive cancer or return to normal (Fig. 2.6) [198]. The chance of progression
or regression depends on the degree of abnormality [207]. Severe forms of CIN
is more likely to progress than regress. To date, the exact mechanism through
which these events take place is still unknown..
Colposcopic and histopathologic observations have shown that all CIN
begins at the squamocolumnar .junction of the epithelium at the transformation
zone contiguous to the native portio epithelium. It is proposed that most CIN
arises from the basal cells in this area [197]. The state of temporary genetic
disarray during the development of the transformation zone may be crucial in the
histogenesis of. CIN. During the process, the columnar. epithelium undergoes
reserve cell hyperplasia leading to squamous metaplasia. If a sexually-
transmitted carcinogen is encountered at an early phase in this physiological
metaplastic process, neoplastic changes will occur. These changes may lead to
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CIN and perhaps eventually to invasive carcinoma [207]. It is still not clear at
which stage of the metaplastic process that the changing epithelium is no longer
susceptible to this carcinogenic effect, but it seems highly probable that the
changes is less likely to occur in mature metaplastic epithelium and the original
stable epithelium.
Several cytologic abnormalities are characteristic to CIN. These include
hyperchromaticity, nuclear pleomorphism, abnormal chromatin pattern and
increased nuclear-cytoplasmic ratio. All grades of CIN may demonstrate
koilocytosis, which is a visible characteristic cytopathologic change caused by
human papillomaviruses. The degree of koilocytosis is proportional to the
number of atypical cells that support HPV replication [197].
(b) Microinvasive squamous cell carcinoma
Microinvasion, although most commonly associated with CIN 3, may occur
in all grades of CIN. Microinvasive carcinoma (MICA) is considered as a
preclinical stage in the progressive neoplastic changes of-CIN and frank clinical
invasive carcinoma of the uterine cervix [206]. It is classified as clinical stage
Ia according to the 1985 FIGO (International Federation of Gynecologists and
Obstetricians) guidelines for staging of carcinoma of the cervix. The definition
of MICA has been controversial with respect to the depth of stromal invasion
as well as the significance of vascular permeation and confluency of invasive
tongues of neoplastic epithelium as related to pelvic node metastasis, vaginal
recurrence, and cancer death. Based on various studies, the Committee on
Nomenclature for the Society of Gynecologic Oncologists in the U.S.A. (SCO)
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proposed a definition of MICA in 1974. It limits the depth of stromal invasion
in MICA to 3 mm or less below the basement membrane of the cervical
epithelium and in which lymphatic or blood vascular involvement is not
demonstrated.
In MICA, the neoplastic cells have abundant cytoplasm and prominent
nucleoli, which are better differentiated than the cells in the associated CIN.
The most reliable criterion in the diagnosis of MICA is the irregular contour of
invading tongues of neoplastic cells.
(c) Invasive squamous cell carcinoma
Squamous cell carcinoma accounts for about 90-95% of all the histologic
types of cervical carcinoma [207]. Approximately 98% of them arise within the
transformation zone. The growth pattern of squamous cell carcinoma may be
endophytic or exophytic. Endophytic carcinomas are either ulcer-infiltrative or
nodulo-infiltrative, whereas the exophytic carcinomas grow out from the surface
of epithelium, often as a polyploid or papillary excrescence. Most of the patients
with clinically visible -invasive carcinoma have abnormal vaginal bleeding.
Intermittent spotting, serosanguineous discharge, frank hemorrhage, rectal pain,
and hematuria are also the commonly encountered symptoms [208].
In general, invasive squamous cell carcinomas are characterized by
anastomosing tongues or solid masses of neoplastic epithelial cells, with irregular
or ragged contour, infiltrating the fibrous stroma of the cervix. In the majority
of cases involving early tumors, CIN may be found in the vicinity of the invasive
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cancer. A number of systems have been proposed to classify squamous cell
carcinoma of the cervix according to the predominant cell type or degree of
differentiation. World Health Organization (WHO) classify the tumors into
large-cell keratinizing, large-cell non-keratinizing, and small-cell non-keratinizing
carcinomas [199]. To date, the most widely used scheme is based on the degree
of differentiation. It divides the invasive lesions into well differentiated (grade
1), moderately differentiated (grade 2), and poorly differentiated (grade 3)
carcinomas. The majority of squamous cell carcinomas are grade 2 tumors,
followed by grade 3 and grade 1 [208].
In the well differentiated type, the most striking features are the circular
whorls of epidermoid cells with central nests of keratin (keratin pearls).
Intercellular bridges_ and cytoplasmic keratinization can also be recognized
among the tightly packed tumor cells with large, irregular, and hyperchromatic
nuclei. In moderately differentiated carcinomas, the cells have large irregular
nuclei and less cytoplasm. Cellular and nuclear pleomorphism is more obvious
than in grade 1 lesions. Although a little keratin formation and individual cell
keratinization can still be seen, keratin pearls are virtually non-existent. Poorly
differentiated carcinomas consist of small, round cells with hyperchromatic oral
nuclei and scant indistinct cytoplasm. There is usually very little feature to
characterize the tumor as of squamous cell origin, apart from its site and growth
pattern, although occasional foci of abortive dyskeratosis can be recognized.
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(d) Adenocarcinoma
Adenocarcinoma of the cervix accounts for about 5% of the cervical
carcinomas. Like squamous cell carcinomas, the tumor may appear exophytic
or ulcerative on clinical examination [207]. The symptoms of adenocarcinoma
are as well similar to squamous cell carcinoma. Abnormal vaginal bleeding is
commonly encountered.
Adenocarcinoma arises from the cervical mucus-secreting glandular
epithelium and can be divided into adenocarcinoma in situ (ACIS) and invasive
adenocarcinoma. ACIS is primarily recognized by cytologic abnormalities, and
is distinguished from the invasive tumor by the following characteristics: (1)
limitation of the lesion to the glandular field (2) admixture of neoplastic and
normal glands and (3) absence of stromal response, such as edema and
inflammatory cell infiltration [209].
About 90% of adenocarcinoma is composed of endocervical columnar
cells containing intracellular mucin. They are arranged in a complex, racemose,
glandular pattern resembles the cleft-tunnel configuration of the normal
endocervical crypts [208, 210]. Like squamous cell carcinoma, adenocarcinoma
varies histologically from well differentiated tumor to poorly differentiated
carcinoma without prominent glandular pattern. The most common type is of
moderate differentiation, in which intracytoplasmic mucin and glandular
structures can be recognized. Other less common subtypes of adenocarcinoma
include endometrioid carcinoma, clear cell carcinoma, medullary




The results of extensive epidemiological studies on cervical cancer has
revealed that it behaves as a venereal disease, with early sexual activity and
multiple sexual partners as the two principal risk factors [197, 206, 207, 211,
212]. Early sexual activity during the active development of the cervical
transformation zone may be important in altering the susceptibility of the
epithelial cells, in this area to carcinogens [201]. The concept of cervical
carcinoma as related to sexual practice is further substantiated by the findings
indicating that women with the carcinoma of cervix have a higher frequency of
getting sexually transmitted diseases such as syphilis, gonorrhea, chlamydial
infection, and trichomoniasis than control groups [208]. Furthermore, women
with high-risk male sexual partners have a higher risk of developing CIN and
cervical cancer [213-215]. Other possible etiological factors include cigarette
smoking [216], use of contraceptive pills [217], and immunosuppression [218].
Since CIN and cervical carcinoma behave as sexually-transmitted diseases,
attempts have been made to identify the possible venereally transmitted
carcinogens. In recent years, it has been found that there is a simultaneous
increase in the incidence of CIN and infections of herpesvirus and
papillomaviruses in both sexes [207]. This observation suggests that there might
be a causal relationship between these viral infections and the carcinogenesis
of uterine cervix.
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The association of herpes simplex virus type 2 (HSV-2) and cervical
carcinoma is suggested by serological and epidemiological evidence. Many
studies have shown that antibodies against HSV-2 are more frequently found in
women with cervical cancer [219]. Moreover, HSV-2 antigens have been
detected by immunofluorescence in the cells exfoliated from CIN and squamous
cell carcinoma of the cervix [220]. However, some recent prospective serologic
studies have demonstrated that no significant relationship exists between HSV-
2 and cervical cancer [221, 222]. In addition to the unsuccessful attempts to
detect HSV-specific DNA and RNA in cervical carcinoma biopsies or cell lines
[223], it was suggested that HSV plays a synergistic role in the carcinogenesis of
genital tumors. It may act as a cofactor or initiator [224] via a hit and run
mechanism [225], or through the insertion of DNA sequences which may behave
as enhancers of cellular gene expression or insertional mutagens [226].
The virus-tumor association of human papillomaviruses and cervical
carcinoma has also been studied extensively, mainly through DNA hybridization
experiments. Up to now, HPV is believed to be the major potential carcinogenic
factor involved in cervical cancer development. The possible etiological role
plays by HPV will be discussed later.
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2.7 Viruses and Bronchogenic Carcinomas
The advances in molecular biology and biotechnology have allowed the
elucidation of the molecular mechanisms involved in the carcinogenesis of lung
cancer. From extensive studies, it is now clear that at least three molecular
events take place in the development of this tumor.
Cytogenetic studies have revealed a consistent deletion of the short arm
of human chromosome 3 (3p14-23) in the majority of SCLC and some non-SCLC
[227-229]. It has been suggested that it may lead to the lost of a cancer
suppressor gene involved in lung cancer [230]. Activation of proto-oncogenes,
especially the myc gene family and the ras gene family, also plays a central role
in the neoplastic process. Amplification or overexpression of myc oncogenes is
frequently encountered in both SCLC and non-SCLC [231, 232], while single
base pair mutational activation, mainly at the codon 12, 13, or 61, of cellular
ras genes is predominantly associated with adenocarcinoma [233]. The final
mechanism by which cell growth may be deregulated is through the action of
various growth factors, such as gastrin releasing hormone (GRP) [234]. and
epidermal growth factor (EGF) [235].
Apart from the abovementioned well documented molecular process,
several recent studies revealed that Epstein-Barr virus and human
papillomaviruses may as well involved in the genesis of lung cancer.
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A. Epstein-Barr virus
A study on the virus-tumor association of EBV and lung cancer in Hong
Kong patients was conducted by Lung et al. in the University of Hong Kong
[236]. -In this study, exfoliated cells harvested from the bronchial washings of 53
patients who had clinically suspected bronchogenic carcinomas were examined
for the presence of EBV DNA by dot hybridization using Barn HI fragment W
as probe. Thirty-three patients of the study group were subsequently diagnosed
as having the malignant disease. It was found that the cells obtained from 19
(58%) of the 33 cancer patients harbor EBV DNA. However, the EBV-
determined antigens, including EBNA, VCA, and EA, were rarely detected in
the cell samples. This finding was found to be consistent with the similar
serological profiles determined in the patients no matter they gave positive or
negative results in the EBV DNA study. Nevertheless, it was suggested that the
lower respiratory tract, in addition to the oropharynx and the parotid glands, is
a major reservoir of EBV, which was believed..to be in a state of viral latency
at this site.
The association -of EBV and bronchogenic carcinoma was also implied in
a more recent study based on serological and histological investigation [237].
The tissue specimen examined was obtained from a 40-year-old female non-
smoker of Southeast Asian origin. The tumor was histologically recognized as
having morphological resemblance with a non-keratinizing variant of NPC, which
was consequently confirmed to be a non-keratinizing poorly differentiated
squamous carcinoma of the lung through ultrastructural examination. The lack
of any symptom related to the nasopharynx as well as the absence of any lesion
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or tumor metastases in the nasopharynx strongly suggested that the tumor is of
pulmonary origin rather than a metastatic manifestation of an occult NPC.
Together with the serological profile of high levels of serum antibodies against
the EBV-determined antigens (especially VCA) in the patient, it was suggested
that the tumor is associated with EBV.
B. Human papillomaviruses
HPV is now believed to be a major potential carcinogenic agent involved
in the development of cervical carcinoma. In 1975, Newell, et al. reported that
white females with a first cancer at the uterine cervix had a 5 to 6-fold excess
risk of developing a subsequent cancer of the oral pharynx, lung, or bladder
within the 5 years after tumor treatment [238]. This clustering in time was
suggested to be due to an etiological or biological relationship between the first
cancer and the second cancer. However, in a recent study, it was argued that the
bronchial carcinoma developed after cervical cancer appears to be a bronchial
metastasis of the latter, instead of, being a second primary cancer [239].
Nevertheless, the association of HPV and bronchogenic carcinomas, 'though
poorly documented, was implied through histological examination and DNA
hybridization studies.
Several histological studies on the neoplastic bronchial epithelium of
invasive squamous cell carcinoma of the bronchus revealed HPV-associated
condylomatous changes [240, 241, 242]. The histologic criteria for making such
a diagnosis include hyperkeratosis, presence of dyskeratotic superficial cells,
papillomatosis, acanthosis, koilocytosis, multinucleation, single cell dyskeratosis,
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and the demonstration of a sharp border between the deep and the more
superficial layers [242]. The lesion was regarded as having condylomatous
changes when six or more of these criteria, including koilocytosis, were fulfilled.
In a study, specimens from 220 patients with invasive squamous cell
carcinoma of the bronchus were examined for the presence of the
abovementioned parameters. It was found that ten cases fulfilled the criteria
of papillomatous condyloma, 6 cases fulfilled those of inverted condyloma, and
51 lesions were histologically similar to flat condyloma [242]. This observation
implied that HPV may be involved in the development of bronchial squamous
cell carcinomas. The author believed that HPV attacks the bronchial epithelium
at the squamocolumnar junction, corresponding to the transformation zone in
the uterine cervix, between the metaplastic squamous epithelium and the native
columnar epithelium. This squamous metaplasia may be induced by carcinogens
or associated with advanced age.
The association of HPV and squamous cell carcinoma of the lung was also
demonstrated in patients associated with juvenile laryngotracheal papillomatosis
(JLTP) as well as laryngotracheobronchial papillomas [243, 244, 245]. In the
cases of JLTP, positive nuclear staining for papillomavirus structural antigens
was demonstrated in bronchial squamous cell carcinomas by in situ hybridization
using peroxidase-antiperoxidase technique. Moreover, through Southern blot
hybridization analysis of the DNA extracted from a patient with laryngeal
papilloma using 32P-labelled probe specific for HPV 11 DNA, Byrne et al. showed
extrachromosomal monomeric HPV 11 DNA in high copy numbers in the
tracheal papillomas, primary lung carcinoma, as well as in a metastatic lymph-
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node tumor [245]. In contrast, HPV 11 DNA was not detected in the normal
tissues of liver and kidney. Moreover, the HPV genome was also found to be
transcriptionally active.
Apart from HPV 11, multiple copies of HPV 16 DNA was as well
demonstrated in an anaplastic carcinoma of the lung [246]. By Southern blot
hybridization analysis, the viral DNA was shown to be integrated into the host
cellular DNA sequence. However, since the patient developed cervical cancer
9 years earlier, a late pulmonary metastasis from the previously treated cervical
cancer could not be ruled out in this case. The authors claimed that the
presence of HPV 16 DNA in this tumor could be significant in two aspects: (1)
if the lung tumor originated from a primary event, it suggests that HPV 16 infections
that certainly prevail in the genital tract may also represent a risk factor for other
localizations. (2) If the tumor would represent a late metastatic event originating
from the cervical tumor, it would demonstrate the persistence of HPV DNA in
metastatic tissue.
Finally, in a recent study, Syrj anen and Syrj anen examined 99 invasive
bronchial carcinoma biopsies by in situ DNA hybridization technique on
formalin-fixed paraffin-embedded specimens with a mixture of labelled probes
related to HPV types 6, 11, 16, 18, and 30 [247]. It was found that HPV DNA
sequences were present in the nuclei of 5 specimens. This study illustrated that
HPV DNA were present in well-characterized bronchial squamous cell
carcinomas.
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2.8 Viruses and Cervical Cancer
A. Epstein-Barr virus
Epstein-Barr virus infection in the uterine cervix is poorly documented.
In 1984, Portnoy, et al. reported a case in which the female patient had painful
genital ulcers developed during the clinical course of primary infectious
mononucleosis [248]. Serologic tests for EBV revealed the presence of
antibodies to VCA and EA, but not EBNA, which is a typical pattern during
acute primary EBV infection. Free virus could be recovered from cord-blood
leukocyte culture by the inoculation of filtered eluates from the cervical and
labial-lesion swabs. The authors postulated that the virus may be produced and
released by the epithelial cells within the ulcer. However, they were unable to
ascertain whether EBV was brought to the ulcer surface by the EBV genome-
carrying lymphocytes in the exudate, which might have been induced to the
productive state of viral replication in the local. environment within the ulcer.
It was also suggested that EBV may be transmitted through a venereal route.
This association was further substantiated by the finding obtained from a
recent study conducted by Sixbey and co-workers [249]. Cervical specimens from
28 women were examined by lymphocyte transformation assay and nucleic acid
in-situ cytohybridization with labelled BamHI V and F fragments of EBV DNA.
Eight of them presented to a university health service with suspected infectious
mononucleosis, while the other twenty women attended a sexually-transmitted
diseases (STD) clinic because of suspected infection. EBV was detected in the
cervical washings obtained from five of them: two with IM and- three. from STD
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clinic. Among them, cell-free infectious virus was found in four of the patients,
while the epithelial cells obtained in the cervical washings of two women were
positive for EBV as revealed by in-situ cytohybridization, in which one patient
gave positive results in both assays. The result obtained in this study is
consistent with the finding that cervical epithelium possesses EBV/C3d receptor
and is capable of expressing viral antigens when infected in culture [250, 251].
It was suggested that the uterine cervix, in addition to the oropharynx, may be
a site for EBV' replication and chronic viral shedding. As the oncogenic role
of EBV has been well documented in nasopharyngeal carcinoma and Burkitt's
lymphoma, EBV may as well play a role in the genesis of cervical carcinoma.
B. Human papillomaviruses
Cervical intraepithelial neoplasia and cervical carcinoma behave as
venereal diseases with early sexual activity and multiple sexual partners as the
two major etiological factors.. Numerous epidemiological studies have suggested
that sexually-transmitted infectious agents with a long latency may be involved
in the carcinogenesis of cervical carcinoma [252]. This suggestion has. led
investigators over the years to evaluate the known genital pathogens as causative
agents for this neoplastic disease [253]. Epidemiologically, infections by
trichomonas, chlamydia, and bacteria, including syphilis and gonorrhea, have not
been linked to cervical carcinoma.
Serological and epidemiological studies suggested that herpes simplex virus
type 2 (HSV-2) may be involved in the development of cervical cancer. -An
excess of antibodies to the virus was frequently encountered among the cases
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of cervical cancer as compared with control groups [219]. However, subsequent
molecular biological studies showed a general lack of consistency in the
demonstration of HSV DNA or RNA in the tumor tissue specimens. On the
contrary, the remarkable frequency with which the nucleic acids of human
papillomaviruses are found in tumor tissues led to the suggestion that HPV may
play an important role in the tumorigenesis of cervical carcinoma.
Human papillomaviruses represent a very heterogeneous group of viruses,
which cause a variety of skin and mucosal papillomatous lesions (Table 2.1).
Direct and circumstantial evidence provided by a large number of studies imply
HPV infection in genital neoplasms. Histological observations revealed that as
many as 70% of cervical dysplasias may be associated with koilocytotic atypia
[254-256]. Koilocyte is a cell with prominent perinuclear space with extensive
margination of cytoplasm, which is a hallmark of HPV infection. HPV structural
proteins was as well detected in CIN by immunohistochemical techniques [257],
while antibodies against the papillomavirus group-specific antigen were detected
in the sera of cancer patients but not in controls [258]. Moreover, it was found
that HPV-associated lesions of the genital tract may undergo malignant
transformation [259] indicating that HPV seems to have oncogenic potential, in
which the latter has already been confirmed in animal papillomaviruses [260].
The most substantive evidence for the etiological role of HPV in cervical
carcinogenesis comes from nucleic acid hybridization studies. HPV DNA has
been demonstrated in a variety of cervical lesions, including condyloma, cervical
intraepithelial neoplasia, verrucous carcinoma, and squamous cell carcinoma
[207]. It is generally believed that the papillomavirus DNA is present in a latent
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state in the cells of the basal layer of squamous epithelium [109]. Several HPV
types are commonly found to be associated with lesions of the female lower
genital tract. Types 6, 11, and 42 are mainly detected in benign genital warts
(condylomata acuminata) and rarely in carcinoma [261, 262], whereas types 16,
18, 33, and some others are mostly associated with neoplastic processes [107].
Among them, HPV 16 seems to be the most prevalent genotype found in cervical
carcinoma samples at a variable frequency in different countries, ranging from
17 to 60% [263, 264]. The prevalence of particular HPV types in benign and
malignant lesions suggested that they seem to be different in their oncogenic
potential.
The physical state of papillomavirus DNA in cervical carcinoma appears
to play a key role in the development of cervical cancer and the maintenance of
malignant state. In HPV-infected benign lesions, the viral DNA usually persists
in the nucleus as extrachromosomal circular episomes whereas in carcinomas,
the HPV DNA is predominantly integrated into the host cell DNA. This
integration does not appear to be specific with regard to the cellular DNA
sequence. However, integration usually. occurs- in a, manner leading to a
consequent disruption--of the El and E2 ORFs [265]. Active transcription of
the viral DNA in tumor cells involving the regions analogous to the more fully
studied bovine papillomavirus, which is known to possess transforming genes
[266], was also demonstrated.
The prevalence of subclinical HPV infection as well as a higher incidence
and later occurrence of cervical carcinoma as compared with CIN implies that
carcinogenesis of the uterine cervix is a multifactorial process [205, 207, 267].
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In the neoplastic process, HPV seems to be one of the trigger factor, which acts
synergistically with other co-factors leading to the consequent cervical carcinoma
[198].
Table 2.1. The clinical association of some characterized human papilloma-
viruses (Ferenczy, A. and Winkler, B., 1987, [197]).
Type Associated lesion
1 Plantar and palinar warts
2 Common warts
3 Juvenile flat warts
A Plantar and common warts
5 EVa
6 Genital condyloma, laryngeal papilloma, GTNb.
7 Butcher's wart
8, 9 EY
10 Juvenile flat wart, EV
11 Genital condyloma, laryngeal papilloma, GTN
12 EV
13 Oral focal epithelial hyperplasia (Heck's disease)
14, 15 EV
16 GTN, Bowenoid papulosis, genital condyloma
17 EV
18 GTN, genital condyloma
19-25 EV
26-29 Immunosuppressed host, EV
30 Immunosuppressed host, laryngeal carcinoma
31 GTN
32 Oral focal epithelial hyperplasia (Heck's disease)
.33 GTN, Bowenoid papulosis
34 Premalignant squamous lesions of skin (actinic kera-
tosis, Bowen's disease)
.35 GTN
36 EV, -premalignant squamous lesions of skin (actinic
keratosis, Bowen's disease, keratoacanthoma)
37 Malignant melanoma
' EV, epidermodysplasia verruciformis.
b GTN, genital tract neoplasia (including intraepithelial neoplasia and
squamous cell carcinoma).
0 One case reported.
Table 2.2. Assignment of papillomavirus gene functions (Howley, P.M. and
Schlegel, R., 1988, [109])
Function a
Gene
E1 Viral DNA replication functions (BPV-1)
Transcriptional regulatory functions: DNAE2
binding protein (BPV-1 and HPV-16)
UnknownE3b
Cytoplasmic protein that may have role inE4
viral maturation (HPV-1)
Cellular transformation, plasmid copy numberE5
control (BPV-1)
Cellular transformation, plasmid copy numberE6
control (BPV-1)
Transcriptional transactivator and cellularE7
immortalization (HPV-16)
E8 Possible role in viral DNA replication (BPV-1)
L1 Major capsid protein (BPV-1)
L2 Minor capsid protein (BPV-1)
aThe functions listed have been primarily assigned by detailed genetic studies
of the bovine papillomavirus numbers in parentheses, the virus in which the
principal studies have been performed.
bNo function has yet been assigned to the E3 ORF. Not all viruses (including
HPV-16) contain an E3 ORF.
Fig. 2.1. Diagrammatic representation of the physical structure of the EBV genome.THe EBV
genome is divided into five domains of unique sequence complexity (U1-U5)bounded by direct
tandem copies of repeated DNA sequences at the terminals of the molecule (TR) and at internal
sites (1R1-lR4). DL and DR represent partial homologous unique sequences which are adjacent
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Fig. 2.3. The structure of Epstein-Barr virus DNA. DNA Isolated from the virus Is a linear double-stranded molecule. TR mediates the circulation of linear
EDsteln-Barr virus DNA In infected cells to generate a circular episomal molecule which is the intracellular form of the genome (Kieff, E., et at., 1982, [33]).
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Fig. 2.4. Genomic organization of BPV-1 DNA. The full-length molecule (7945 base pairs) of BPV-1 DNA Is opened at the unique HindIII site.
The direction of transcription Is indicated by the arrow at the top of the figure. The open bars are the ORFs which represent potential coding
exons for the viral genome. ORFs within the transforming region are designated El to E8, and the numbers beneath the ORFs indicate the first
and last bases of the ORF. The Li and L2 ORFs are expressed only In productively Infected tissues. The general features of the BPV-1 genome
are characteristic of each of the papillomavirus genomes sequenced thus far (Sarver, N., et al., 1984, [121]).
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Fig. 2.5. Schematic representation of cervical cancer precursors. Grade 1, 2, and 3 CIN correspond to the traditional very mild to mild,
moderate, and severe dysplasla to CIS, respectively. They are characterized by a progressive Increase In the number of undifferentiated,
malignant cells with nuclear aneuploidy and a decrease In superficial cell differentiation of koilocytotic cells paralleling the Increase in severity
of CIN (Ferenczy, A. and Winkler, B., 1987, [197]).
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3.1 The Nucleic Acid Probes
A. Human Papillomaviruses
The four HPV DNA probes employed in this study were kindly provided
by Professor H. zur Hausen and Dr. L. Gissmann (Deutsches Krebsforchung-
szentrum, Heidelberg, Federal Republic of Germany). Three of them consisted
of full-length genomic DNA from HPV 11 [268], HPV 16 [269], and HPV 18
[270] respectively as inserts in the plasmid vector pBR 322. The fourth one,
HPV 6 [271], was obtained as two EcoRI/BamHI subgenomic fragments cloned
separately at the BamHI and EcoRI cleavage sites of pBR 322. The relevant
information of the HPV DNA probes was listed in table 3.1.
B. Epstein-Barr Virus
In contrast to HPV, the large size of EBV full genomic DNA makes it
impossible to be employed as probe. Hence, the EBV BamHI- H,- K, and-
W fragments of B95-8 virion DNA [272] were used. These EBV BamHI
fragments were gifts from the Medical School of Harvard University as inserts
in pBR 322. Since all of the three fragments encode the EBV transforming
antigen EBNA [38, 39, 77, 273, 274] which was found to be expressed in all
EBV-infected human cells [95], they can be used as markers to demonstrate the
58





The lung tissue specimens of Hong Kong Chinese patients were provided
by Dr. Muoi Arnold of the Department of Morbid Anatomy, CUHK. The study
group consisted of 23 surgical cases and 5 'autopsy cases presented at Prince of
Wales Hospital and Kowloon Hospital. The 28 tissue samples were examined
histologically and classified into different histologic types as well as various
degrees of differentiation as formulated by the World Health Organization
(WHO) in 1981 [157]. There are totally 19 cases of adenocarcinomas, 1 case
of small cell carcinoma, 7 cases of squamous cell carcinomas, and 1 case of large
cell carcinoma. For each patient, both the tumor and normal control tissue
specimens were collected. The matched internal-control tissue was obtained
from the distant resection margin of the bronchopulmonary segment or lobe
removed with the tumor, which was histologically confirmed to be normal.
All the tissue samples were frozen at -70° C before they were processed
for DNA extraction. The histologic diagnosis of the bronchogenic carcinomas
investigated are presented in table 3.3.
B. Cervical carcinoma
The sample group consisted of one surgical tissue specimen and 14
colposcopically directed cervical punch biopsy specimens of Hong Kong Chinese
patients. The biopsies were collected by Dr. William Fu of the Department of
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Clinical Oncology from the women presented in Li Ka Shing Specialist Clinic of
Prince of Wales Hospital. The tissue samples were histologically proved to be
cervical carcinomas by the Department of Morbid Anatomy. Of the 15 tumor
tissue specimens, 14 were diagnosed as squamous cell carcinomas while the
remaining one was classified as adenocarcinoma according to WHO guidelines
[199]. Apart from the tumor tissues, a biopsy which was confirmed to be cervical
intraepithelial neoplasia grade II (CIN II) was given by Dr. Felix Wong of the
Department of Obstetrics Gynecology, CUP]K. Strips of histologically normal
ectocervical and endocervical (including the transformation zone) epithelium
were as well provided by Dr. May Chan of the Department of Morbid Anatomy,
CUHK. These epithelial tissues were dissected from the cervices of two women
undergoing hysterectomy for benign diseases who had no previous history of
abnormality of the uterine cervix.
The tissue samples were kept at -70° C until processed for DNA extraction.
The relevant histopathological- features are shown, in table 3.4.
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3.3 Cell Cultures and Xenografts
A. The cervical carcinoma cell line-
CC3
CC3 is an established cell line derived from a well differentiated squamous
cell carcinoma of uterine cervix taken from a Hong Kong Chinese patient
(unpublished work). It was developed and provided by Dr. E.C. Chew of the
Department of Anatomy, CUHK.
CC3 (Fig.3.1) was cultured in RPMI 1640 (Sigma) supplemented with
10% fetal calf serum (GIBCO Laboratories), 100 units/ml penicillin, 100 µg/ml
streptomycin sulfate, and 2mM L-glutamine (GIBCO Laboratories) at 37°C in
a humidified atmosphere of 5% carbon dioxide maintained in a water jacketed
incubator (Forma Scientific). The medium was changed twice a week and the
cells were passed into four tissue culture flasks, (Nunc, 80cm2/260 ml), each
containing 15 ml fresh medium, when. confluency was achieved (about 2.2x10'
cells in 80cm2/260 ml culture flask). For harvest and subculture, the cell
monolayers were trysinized with 0.25% trypsin/1mM EDTA (GIBCO
Laboratories) for 3-5 minutes at 37°C. The cells were then pelleted at 500 g
for 10 minutes (Digifuge, Heraeus Christ) and resuspended in fresh medium
for subculture or washed twice with ice-cold phosphate-buffered saline for DNA
extraction.
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B. The Raji cell line
This Epstein-Barr virus-carrying nonproducer lymphoblastoid cell line was
established over 20 years ago from a culture of an African Burkitt's lymphoma
biopsy [4, 275]. Raji cells each contains about 50 copies of EBV DNA in an
episomal, circular form [45, 50, 51, 52, 276, 277]. However, there may also exists
one or more integrated viral genomes [278]. Recent work demonstrated the
presence of two major defective nucleotide sequences in the EBV DNA of Raji
cells [56, 279]. The absence of viral DNA replication in this nonproducer cell
line may be the result of inactivation of early genes localized at these defective
regions [280].
The Raji cell line was grown in RPMI 1640 medium (Sigma) containing
10% fetal calf serum (GIBCO Laboratories) with 100 units/ml penicillin and
100µg/ml streptomycin sulfate (GIBCO Laboratories) at 37 0 C as described
before. Since Raji cells grow in suspending form, they were harvested by
centrifugation at 500 g for 10 minutes (Digifuge, Heraeus Christ). The DNA
extracted from them were employed as the positive control in the EBV studies.
C. BALB/c 3T3 cells
The BALB/c 3T3 fibroblast cells were cultured in Dulbecco's modified
Eagle's medium (Sigma) supplemented with 10% fetal calf serum (GIBCO
Laboratories), penicillin at 100 units/ml, and streptomycin sulfate at 100 µg/ml
(GIBCO Laboratories) at 37° C as described before. The cells were harvested
by trypsinization and DNA was extracted which was used as the negative control
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in the EBV and HPV studies.
D. The cervical cancer xenografts
The xenografts derived from the cervical carcinoma cell line, CC3, were
prepared by Dr. Dolly Huang and Mrs. Angela Jen in our laboratory.
Heterotransplantation of athymic nude mice was performed at passage 41.
Confluent CO cell monolayers were harvested by trypsinization and resuspended
in RPMI 1640 (Sigma). The nude mouse was inoculated subcutaneously with
1.7x10' viable cells in 0.5 ml blank medium by a 1 ml syringe with number 16
gauge stainless steel needle. The animal was maintained in a sterile
environment and was observed daily. The tumor developed was designated
CC3PO (Fig. 3.2).
CC3PO was removed on the 42th day after heterotransplantation of CO
cells. Part of the xenograft was minced into ..tiny fragments under. aseptic
condition which was then suspended in blank RPMI 1640 medium (Sigma) and
transplanted subcutaneously, into a second ...group of: nude mice as described
before. The xenograft obtained was designated CC3P1 (Fig. 3.3). Both CC3PO
and CC3P1 were kept at -70 0 C before they were processed for DNA extraction.
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3.4 Extraction of Genomic DNA
A. Cultured cells
High -molecular weight genomic DNA was extracted by the phenol-
chloroform method [281]. Cultured cells were harvested either by trypsinization
or direct centrifugation at 500 g for 10 min (see Section 3.3). After the cells
had been washed twice with ice-cold isotonic phosphate-buffered saline', they
were spun down in a 50-ml Falcon conical centrifuge tube as described above.
The pelleted cells were then digested overnight at 55° C in 10 ml of STE2
containing 0.5% SDS3 and 0.2 mg/ml of proteinase V. Following overnight
incubation, the solution was cooled and the cellular DNA was extracted by
mixing gently with 10 ml of ice-cold phenol-chloroforms for 10 min. The mixture
was then freezed at -20° C for 10 min and spun at 2000 g for 20 min (Digifuge,
Heraeus Christ). The upper aqueous phase was collected by an inverted 1-ml
pipette and the DNA was precipitated by mixing with one-tenth volume of 3 M
sodium acetate (pH 5.2) and two volumes of freezed 95% ethanol6. The DNA
precipitate was pelleted at 2000, g for 20 -min, washed once with freezed 70%
ethanol', and dissolved in 5 ml of TE, pH 7.58. Any RNA present was digested
by :100 µg/ml DNase-free RNase A9 for 2 hr at 37° C. The enzyme was in turn
broken down by 0.5% SDS together with proteinase K at 100 µg/ml for 1 hr at
55° C. The DNA was again extracted with phenol-chloroform, precipitated with
ethanol, and dissolved in TE, pH 7.5. The yield of DNA was finally determined
spectrophotometrically after dialysis for 2 days against several changes of TE
at 4°C.
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The yield and purity of the DNA obtained was determined by measuring
the absorbance of the diluted DNA sample at 260 nm, 280 nm, and 330 nm
using the Gilford Response UV-VIS spectrophotometer.
Purity check:
The ratio of (A260 - A330)/ (A280 - A330) = 1.8 to 2.0
DNA concentration (µg/ml):
DNA conc.= (A280 - A330) x DF x 50
(1 unit absorbance at 260 nm = 50 µg/m1 DNA)
where A260 = absorbance at 260 nm
A280 = absorbance at 280 um
A330 = absorbance at 330 nm
DF = dilution factor
REAGENTS
Phosphate-buffered saline (PBS): contains 145 mM NaCI (BDH), 12.4 mM1.
Na2HP04.12H20 (BDH), 2.5 mM KH2PO4 (BDH). The pH value was
adjusted to 7.4 before autoclave.
STE: contains 0.1 M NaCl (BDH) 0.05 M Tris buffer (Sigma), pH 7.52.
and 1 mM EDTA (Sigma). pH 7.4. Autoclaved.
3. 10% SDS: 10 g SDS (Sigma) in 100 ml autoclaved double distilled water.
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4. Proteinase K: 20 mg/ml proteinase K (Sigma) in 10 mM Tris buffer
(Sigma), pH 7.5. Stored at -20 0 C.
5. Phenol-chloroform: prepared by mixing liquefied phenol (Mallinckrodt),
chloroform (BDH), and isoamyl alcohol (Sigma) in a ratio of 25:24:1
(v/v/v) in 2 mM Tris buffer (Sigma), pH 8.1 for 3 hr in a dark bottle. The
mixture was stored at 4 0 C in the dark.
6. 95% ethanol: absolute ethanol (BDH) and autoclaved double distilled
water mixed in a ratio of 19:1. Freezed at -20° C.
7. 70% ethanol: absolute ethanol (BDH) and autoclaved double distilled
water mixed in a ratio of 7:3. Freezed at -20 0 C.
8. TE: contains 0.1 mM EDTA (Sigma), pH 7.4 and 1 mM Tris buffer
(Sigma), pH 7.5. Autoclaved.
9. RNase A: 10 mg/ml Ribonuclease A (Sigma) in 10 mM Tris buffer
(Sigma), pH 7.5. Boiled in boiling water bath for 10 min. Stored at-
20° C.
B. Tissue samples and xenografts
The tissue samples and xenografts collected were stored at -70° C before
they were processed for DNA extraction. To prepare DNA from them, frozen
tissues were allowed to thaw and then minced into tiny pieces with sharp scalpel
or scissors. Proteinase K-SDS digestion was carried out in a 50-ml Falcon
conical centrifuge tube and the cellular DNA was extracted and quantitated in
exactly the same way as described for cultured cells. The DNA samples obtained
were stored at -20 0 C for future use.
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3.5 Preparation of Cloned Probe DNA
A. Culturing of bacteria
E. coli HB101 was stored at -70,, C as glycerol cultures. In order to grow
a fresh culture for competent cell preparation or subculturing, a small inoculum
of the frozen bacterial stock was directly streaked on LB (Luria-Bertani) agar
plate (Table 3.5) with a sterile inoculating loop. After overnight incubation at
37 0 C, single isolated colony was picked and inoculated into LB broth medium
(Table 3.6). A fresh batch culture was obtained thereafter by overnight
incubation at 37° C with good aeration. To prepare the bacterial cells in bulk,
the above overnight seed culture was inoculated and grown in a larger volume
of LB broth.
B. Preparation of competent cells
The competent cells were prepared by calcium chloride treatment. One
ml of an overnight culture of E. coli HB101 was inoculated into 500 ml LB broth
which was then incubated with vigorous shaking at 37° C until the absorbance
at 550nm was about 0.5 (approx. 5x107 cells/ml). The bacterial culture was
immediately chilled in ice bath for 10 min. The chilled cell suspension was then
pelleted at 4' C by centrifugation at 2000g for 20 min (International centrifuge
IEC M-25, Rotor 890, IEC). After discarding the supernatant, the cell pellet
was resuspended in 250 ml ice-cold 0.1 M CaC12 and mixed gently by sucking
up and down with a 10-m1 pipette. Once the bacterial cells were well
resuspended, the culture was incubated on ice for 30 min with occasional
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agitation before it was pelleted once again as described above. The cell pellet
was then resuspended in 10 ml ice-cold 0.1M CaCl2i 20% (v/v) glycerol. After
standing on ice for further 30 min, the cell suspension was dispensed in 300 Al
aliquots into pre-cooled sterile Eppendorf tubes in ice. The prepared competent
cells were freezed quickly in liquid nitrogen and kept at -70° C.
C. Transformation of competent cells
The CaC12 treated competent cells (50 ul per Eppendorf tube) were
allowed to thaw at 4° C. Before completely defrosted, they were put on ice and
left there for 5 min before transformation. Ten ng of recombinant plasmid
DNA in TE buffer', less than 1 µl in volume, was added and the mixture was
incubated in ice bath for 20 min. The cells were then heat-shocked in 37° C
water bath for 1.5 min and freeze-shocked in ice-water bath for 5 min.
Afterwards, 500 µl pre-warmed LB broth was added to each Eppendorf tube
and the transformation mixture was incubated without agitation at 37 0 C for 1
hr. One-tenth of the transformants was finally spread onto LB agar plates
containing the appropriate antibiotics2, which were then incubated at -37.a C
overnight.
Isolated colonies of the transformants appeared on the agar plates the
other day were picked with a flame-sterilized inoculating loop and streaked
directly on selective media3 to check for the presence of drug-resistance markers
(such as Amp`, Tet`). After the identity of the transformants was confirmed,
the bacterial culture was grown in bulk for plasmid purification or kept at -70° C
in 15% glycerol4.
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REAGENTS & CULTURE MEDIA
1. TE buffer: contains 0.1 mM EDTA (Sigma) pH 7.4 and 1 mM Tris buffer
(Sigma), pH 7.5 autoclaved.
2. Ampicillin: 25 mg/ml solution of the sodium salt of ampicillin (Sigma) in
distilled water. Sterilized by filtration and stored at -20,, C.
Tetracycline: 12.5 mg/ml solution of tetracycline hydrochloride (Sigma) n
ethanol/water (50%, v/v). Sterilized by filtration and stored at -20° C in
the dark.
3. Selective media: LB agar plates (Table 3.5) with 50 µg/ml ampicillin or
12.5 jcg/ml tetracycline.
4. Glycerol stock: transfer 0.85 ml of overnight culture (in LB broth containing
50µg/ml ampicillin) to a sterile vial containing 0.15 ml of sterile glycerol
(BDH).
D. Growth of transformants
Plasmids are replicons which are stably inherited in an extrachromosomal
state and are able to replicate independent of the bacterial genome. Plasmids
with Col El replicon. or Col El replicon-like replication origin, such as pBR
322 in which the HPV and EBV DNA probes (Table 3.1 and 3.2) are cloned,
can be amplified by chloramphenicol treatment [282]. However, since
chloramphenicol stops bacterial cell growth through the inhibition of prokaryo-
tic protein synthesis, it is important to apply the antibiotic to a low-density,
rapidly growing culture (usually at the late logarithmic phase). In order to
monitor the timing of chloramphenicol treatment, the growth curves of two
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transformants (E. coli HB101 that harbors the recombinant plasmids carrying
HPV 16 and HPV 18 DNA inserts respectively) were determined.
In a 250-ml conical flask, 0.5 ml of an overnight culture was inoculated
into 100 ml of fresh LB broth medium containing 50 µg/ml ampicillin (Sigma).
The culture was incubated at 370C with shaking at 150 rpm. Growth was
monitored in terms of culture turbidity measured with Klett-Summerson
photoelectric colorimeter Model 8003 fitted with No. 66 filter (Arthur H.
Thomas Company).
E. Isolation of plasmid DNA from amplified cultures
Plasmids are stably inherited in appropriate bacteria. When litre amounts
of bacteria carrying the recombinant plasmids are grown, milligram quantities
of the latter can be obtained. It is done by lysing the bacteria and purifying the
plasmid DNA away from the* bacterial chromosomal DNA sequences through
cesium chloride-ethidium bromide centrifugation [281].
Five ml of an overnight culture of E. coli HB101 carrying the recombinant
plasmid was inoculated into 1 litre of LB broth containing 50 µg/ml ampicillin
(Sigma). The bacterial culture was grown at 37 0 C with vigorous shaking for
about 8 hr (an absorbance at 550 nm of about 0.5 was reached). In order to
improve the yield of plasmid DNA, chloramphenicol (Sigma)1 was added to 200
µg/ml, and the culture was again incubated overnight with shaking at 37° C.
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The cells of the chloramphenicol-amplified culture were harvested by
centrifugation at 2000 g for 20 min (Digifuge, Heraeus Christ). The cell pellet
was resuspended in 36 ml of freshly prepared solution r containing 10 mg/ml
lysozyme (Sigma) and left at room temperature for 10 min. The cells were then
lysed by mixing the cell suspension thoroughly with 80 ml of freshly made ice-
cold solution IV by gently inverting the tube several times. After standing on
ice for 5 min, 40 ml of ice-cold solution III4 was added and the mixture was
incubated in ice bath for 30 min to precipitate the high molecular weight
bacterial chromosomal DNA and cell debris. The precipitate was removed by
centrifugation at 15000 rpm for 20 min at 40C (International Centrifuge IEC
M-25, Rotor 890, IEC). The plasmid DNA in the supernatant was then
precipitated with 0.6 volume of isopropanol (BDH) and kept at -20° C overnight.
The precipitated DNA was collected by centrifugation at 2000 g for 20
min (Digifuge, Heraeus Christ). Then 0.7 ml of 1 M Tris buffer (pH 8.0) was
added to the pellet and the suspension was made-up to 8 ml with TE (pH 8.0)5.
To the DNA solution, 9 g of cesium chloride (Pharmacia) was added and mixed
gently until all the salt was dissolved:- Finally, 1 ml ethidium bromide (10
mg/ml, Sigma) was added and the mixture was transferred to two Beckman
Ultra-Clear'' centrifuge tubes (13 x 51 mm) and spun at 40000 rpm for 75 hr
at 20 0 C (Beckman L8-70M Preparative Ultracentrifuge, Rotor SW 50.1). Since
covalently closed circular DNA such as plasmid binds less to ethidium bromide
due to topological constraints, hence plasmid DNA has a. higher density.. than
bacterial chromosomal DNA at saturating concentrations of ethidium bromide.
As a result, two bands were observed under UV illumination (UVL-21 Blak-
Ray Lamp, UVP, Inc.) after cesium chloride-ethidium bromide centrifugation.
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The lower band, consisted of closed circular plasmid DNA, was collected into
Eppendorf tubes with a syringe by puncturing the side of the centrifuge tube
about 0.5 cm below the DNA band with a 18-gauge hyperdermic needle.
The ethidium bromide in the plasmid DNA was removed by extracting 3
to 4 times with cesium chloride-water saturated isopropanol6 until no pink color
was observed in the lower aqueous phase. Three volumes of TE was then added
and the DNA was precipitated with 2.2 volumes of ice-cold absolute ethanol
and freezed at -70° C for 3- 4 hr. The plasmid was finally pelleted by
centrifugation at 13000 rpm for 20 min (Micro Centaur, MSE), dissolved in TE
(pH 7.5), and dialysed against several changes of TE (pH 7.5) at 4° C. The yield
of the plasmid DNA was determined spectrophotometrically (see Section 3.4)
and the DNA was stored at -20° C.
REAGE rrs
1. Chloramphenicol: 34 mg/ml solution of crystalline chloramphenicol (Sigma)
in absolute ethanol, stored at -20 0 C.
2. Solution P. contains 50 mM glucose (BDH) 25 mM Tris buffer (Sigma),
pH 8.0 10 mM EDTA (Sigma).
3. Solution II: contains 0.2 N NaOH (BDH) 0.1 g/ml SDS (Sigma).
Solution III: 5 M potassium acetate, pH 4.8 prepared by mixing 60 .ml of4.
5 M potassium acetate (BDH) with 11.5 ml of glacial acetic acid (BDH),
and 28.5 ml of distilled water.
TE (pH 8.0): contains 0.1 mM EDTA (Sigma), pH 8.0, and 1 mM Tris5.
buffer (Sigma), pH 8.0.
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6. Cesium chloride-water saturated isopropanol: prepared by dissolving cesium
chloride (Pharmacia) in distilled water to the extent that there was some
undissolved cesium chloride, which was then mixed with isopropanol
(BDH) until saturation. The upper isopropanol phase was used.
F. Purification of probe DNA by electroelution [281, 283]
The DNA probe was freed from the cloning vector by digestion with the
restriction endonuclease (BDH) used initially in the cloning procedure (Table
3.1 3.2), under the conditions recommended by the manufacturer. Typically,
in a reaction volume of 20 µl, 1 µg of DNA was mixed with 2 µl of lOX reaction
buffer (supplied by the manufacturer) and 2 units of restriction enzyme in an
Eppendorf tube. After making up the reaction volume with autoclaved double
distilled water, the reaction mixture was incubated at 37 0 C for 10-15 hr. The
digestion was stopped by adding 0.8 µl of 0.5 M EDTA, pH 8.0.
The digested DNA samples were heated at 68 0 C for 10 min, quickly
chilled on ice, and then mixed with 4 µ16X gel-loading buffer'. Using 1X TBE2
as the electrophoresis buffer, the DNA samples, including size markers3, were
fractionated through 0.8% agarose gel containing 0.1 µg/ml ethidium bromide4
in a horizontal gel electrophoresis system (Model H3, BRL) at 30-40 V for 15
hr. The electrophoretic pattern was visualized by UV illumination
(Transilluminator TS-36, Ultra-violet Products, Inc.) and recorded by Polaroid
MP-4 land camera using Polaroid 667 film (ASA 3000). The slice of agarose
containing the band of interest was cut out with a sharp scalpel and placed into
a prepared dialysis tubing (BRL) filled with 0.5X TBES. The dialysis bag was
then immersed in a shallow layer of 0.5X TBE in an electrophoresis tank. The
74
DNA probes were electroeluted out of the gel onto the inner wall of the tubing
by passing current through the bag for 2 hr at 100 V. In order to push the DNA
back into the electrophoresis buffer, the polarity of the current was reversed for
about 3 min and all the buffer in the dialysis bag was then collected by a Pasteur
pipette.
The DNA probes were concentrated by Centricon-30 (Amicon) according
to the conditions recommended by the manufacturer. After the identity of the
probe was confirmed by gel electrophoresis through 0.8% agarose minigel
(Mndel Nh Rabv Gel. BRL. it was stored at -20 0 C.
In the study of HPV 16 in the cervical cancer cell line CO and the nude
mouse xenografts derived from it, subgenomic fragments of HPV 16 were
isolated as probes (Fig. 3.4). It was done by digesting the purified linear HPV
16 full genomic fragment with PstI, followed by gel electrophoresis and
electroelution as just described.
REAGENTS
1. 6Xgel-loading buffer. contains 2.5 mg/ml bromophenol blue (BDH) 2.5
mg/ml xylene cyanol (Sigma) and 30% glycerol (BDH) in water (v/v).
Stored at 4° C.
2. 1X TBE: contains 0.05 M Trizma Base (Sigma) 0.05 M boric acid (BDH)
and 2.5 mM EDTA (Sigma). pH value was adjusted to 8.0 before
autoclave.
3. Sue marker: lambda DNA/HindIll fragments in TE, pH 7.4 (BRL).
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4. 0.8% agarose gel: 1.2 g agarose (Sigma) dissolved in 150 ml 1X TBE.
5. 0.5X TBE: 2-fold dilution of 1X TBE.
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3.6 Radioactive Labelling of Nucleic Acid Probes
A. Random primer extension
Detection of the hybrids formed between DNA probes and target
sequences can be achieved-by labelling the probe DNA either non-isotopically
or isotopically. In the present study, the HPV and EBV DNA probes were
radioactively labelled with [a 3P]dC'IP (PB.10205, Amersham)' by employing a
multiprime DNA labelling system (RPN.1601, Amersham) [284, 285].
In the standard reaction condition, 25 ng of DNA probe in a volume of
1-10,41 was denatured by heating in boiling water bath for 2 min. After chilling
on ice for 5-10 min, the denatured probe DNA was mixed with 10,41 of Solution
12, 5µl of Solution 23, 5 µl of [a 32P]dCTP, and 2µl of Solution 34. The volume
of the reaction mixture was made up to 50 Al with autoclaved double distilled
water and incubated overnight at room temperature. The reaction was stopped
the other day by adding 2 µl of 0.5M EDTA, pH 8.0.
REAGENTS
1. [a-32P]dCTP (PB.10205): 10 mCi/ml in stabilized aqueous solution, with
a specific activity of about 3000 Ci/mmol (110 TBq/mmol).
2. Solution 1 (Multiprime buffer solution): contains dATP, dGTP, and dTTP,
in a concentrated buffer solution consisting of Tris-HC1, pH 7.8
magnesium chloride and 2-mercaptoethanol.
3. Solution 2 (Primer solution): Random hexanucleotides in an aqueous
solution containing nuclease-free BSA.
77
4. Solution 3 (Enzyme solution): 1 unit per µl DNA polymerase I Klenow
fragment in 50 mM potassium phosphate, pH 6.5, 10 mM 2-mercapto-
ethanol and 50% glycerol.
B. Precipitation with trichloroacetic acid
In order to determine the specific activity and the amount of radioactivity
that had been actually incorporated into the DNA probes, trichloroacetic acid
(TCA) precipitation was performed.
One 41 of the reaction mixture was diluted to 200 Al with 0.2 M EDTA
(pH 8.0). After setting aside 100 µl of the diluted DNA sample for the
determination of total input radioactivity, the remaining sample was mixed with
50 µl of carrier DNA solution' (Solution 5 of the Amersham Multiprime
Labelling Kit, RPN.1601) and 2 ml of ice-cold 10% TCA2. The mixture was
then incubated in ice bath for 15 min before the precipitated DNA was collected
by filtration on a glass fibre disc. Following a wash with 2 ml of ice-cold 10%
TCA, the disc was dried thoroughly under a lamp. The disc was then dipped
into 1 ml of Beckman Read-Sole multi-pltrpose liquid scintillant cocktail and
the radioactivity. incorporated into the probe DNA was determined by liquid
scintillation counting (Beckman LS 9800 liquid scintillation counter). The total
input radioactivity was counted similarly by mixing the 100µ1 diluted sample with
1 ml of scintillant cocktail.
The percentage of incorporation of [a 32P]dCTP, the total amount of DNA
probe produced at the end of the labelling procedure, the total activity, as well
as the specific activity of the DNA probe can be calculated as follows:
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% Incorporation= (radioactivity on disc/ total input radioactivity) X 100%
Total amount of DNA (ng)_
(total amount of AG added x 13.2 x% incorporation)/(specific activity of
[a-32P]dCTP added) + amount of input DNA
Total activity (cpm) = radioactivity on disc X 2.01 X V
where V = volume of labelled DNA
Specific activity (cpm/µg) = total activity / amount of labelled probe DNA
REAGENTS
1. Carrier DNA: 100 µg/m1 of salmon sperm DNA in 20 mM EDTA solution.
2. 10% trichloroacetic acid (TCA): prepared by dissolving 50 g TCA (Sigma)
in 227 ml autoclaved double distilled water. Stored at 4°C.
C. Removal of unincorporated label
In order to minimize the degree of non-specific binding during
hybridization, the unincorporated [a-32]dCTP was removed together with the
free non-radioactive deoxynucleotides in the Multiprime buffer solution by using
a spun-column.
The spun-column was set up in a 1-ml disposable syringe with Sephadex
G-50 (Pharmacia) equilibrated in STE1 as described by Maniatis et al. [281].
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The syringe was then inserted into a plastic centrifuge tube with a decapped
Eppendorf tube fixed at the bottom. The column was centrifuged at 1600 g for
4 min (Digifuge, Heraeus Christ) and the packed gel-bed volume was adjusted
to 0.9 ml. After the column had been washed twice with 0.1 ml of STE through
centrifugation under the same conditions, the labelled DNA sample (in a total
volume of 0.1 ml, made up with STE) was applied. The column was again spun
at 1600 g for 4 min and the effluent (should be 0.1 ml in volume) was collected
in the decapped Eppendorf tube.
REAGENT
1. STE: contains 0.1 M NaCl (BDH), 0.05 M Tris buffer (Sigma), pH 7.5,
and 1 mM EDTA (Sigma), pH 7.4 autoclaved.
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3.7 Immobilization of DNA on Solid Support
A. Dot blot/ Spot blot
Dot blot is a rapid and sensitive method, though not as specific as
Southern blot, for screening multiple DNA samples for the detection of
infectious agents or other abnormalities in pathologic specimens. In the present
study, the tumor-virus association of HPV 6/11 and bronchogenic carcinomas
was investigated by the Bio-Dotes microfiltration apparatus (Cat. No. 170-6545,
Bio-Rad). The set up of the Bio-Dot apparatus is shown in Fig. 3.5.
A nitrocellulose membrane was prepared for DNA binding by soaking in
autoclaved double distilled water for 20 min and immersed in 20X SSC' for
another 20 min. The wet filter was placed on the 96 well sealing gasket, which
was aligned above the support plate situated on the vacuum reservoir. The 96
well sample template was finally put in place on the nitrocellulose membrane
and the entire assembly was held together by four sealing screws. The apparatus
was then connected to a vacuum source controlled by a 3-way flow valve. The
tightness of the assembly was ensured by tightening up the screws while vacuum.
was applied in order to prevent well-to-well leaking.
DNA samples (1- 10 jhg) were denatured in boiling water bath for 10 min
and chilled immediately on ice. After washing each well with 100 µl of 20X SSC,
the denatured DNA samples were applied and vacuum-filtered on the
sample wells were then washed with 1- Mnitrocellulose membrane. The'
ammonium acetate and the membrane was harvested. After baking the filter
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at 80°C for 2 hr, it was stored in desiccator for future hybridization.
REAGENT
1. 20X SSC: contains 3 M NaCl (BDH), 0.3 M sodium citrate (BDH), pH
7.0.
B. Southern blot
Southern blot was developed by E.M. Southern in 1975 [286]. This method
involves the. transfer of 'size-fractionated DNA restriction fragments from a gel
matrix to a solid support. It is the principal technique employed in the present
study.
Ten microgram aliquots of genomic DNA samples were digested to
completion with the appropriate restriction enzymes (BRL) under the conditions
recommended by the manufacturer, and subjected to electrophoresis through
0.8% agarose gel (see Section 3.5F).- After staining the DNA by 0.6 µg/ml
ethidium bromide (Sigma) in 1X TBE' for 30 min at room temperature, the
electrophoretic pattern *was recorded as described before (see Section 3.5F).
The DNA fractionated in the agarose gel was then denatured by soaking the
gel twice in denaturing bathe for 20 min at room temperature with shaking.
Following neutralization in neutralization solution3 twice for 20 min, the DNA
was blot transferred onto nitrocellulose membrane employing the DNA. blot
transfer system (BRL).
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A piece of Whatman 3MM paper sheet wet with neutralization solution
was placed on a plastic support in a tray containing 20X SSC, which was used
as the transfer buffer (Fig. 3.6). The inverted gel, with the original underside
became uppermost, was placed on the damp paper wick. A nitrocellulose filter,
wet with autoclaved double distilled water and 20X SSC (see Section 3.7A), was
then laid on the gel. The DNA was transferred upward from the gel onto the
filter through the absorption of buffer by a stack of blotting pads placed on the
membrane with 3 sheets of Whatman 3MM paper (wet with 20X SSC) in
between and a weight of 0.5-1 Kg on the top. Transfer was allowed to proceed
for 18-24 hr 'before the nitrocellulose filter was harvested, baked at 80 0 C for 2
hr, and stored in desiccator for future hybridization.
REAGENTS
1. 1X TBE: contains 0.05 M Trizma Base (Sigma) 0.05 M boric acid (BDH)
and 2.5 mM EDTA (Sigma). pH value was adjusted to 8.0 before
autoclave.
2. Denaturing solution: contains 1.5 M NaC1(BDH) and 0.5M NaOH (BDH).
Neutralization solution: contains 1.5 M NaCI (BDH) and 1 M Tris buffer3.
(Sigma), pH 8.0.
4. 20X SSC: contains 3 M NaCl (BDH), 0.3 M sodium citrate (BDH), pH
7.0.
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3.8. Nucleic Acid Hybridization
Hybridization involves the sequence-specific base pairing of two
complementary nucleic acid strands. By varying the stringency of hybridization,
target gene sequence closely related to or identical to the labelled probe can
be detected. It involves three essential steps: prehybridization (site saturation),
hybridization and stringency washing.
Nitrocellulose membrane, with DNA blot transferred onto it, was wet
thoroughly in prehybridization solution lacking denatured sonicated salmon
sperm DNA (Sigma)'. The membrane was then put into a plastic bag and
prehybridization solution was added (1 ml/10 cm2). The prehybridization
solution was composed of 5X SSPE2, 50% formamide (Sigma)3, 5X Denhardt's
solution [287]4, 0.5% SDSS, and 150 µg/ml of denatured sonicated salmon sperm
DNA. After prehybridization for 6-8 hr at 42° C, the prehybridization solution
in the bag was replaced with hybridization solution. It was made up of prehy-
bridization solution containing denatured [cx 32P]dCTP labelled probe6 at 1- 2 x
106 cpm/ml. Hybridization was performed at 42 0 C for 16-20 hr before stringency
washing was carried out as listed in Table 3.7- 3.9. The filters were finally
wrapped in Glad Wrap and exposed to Kodak X-OMAT AR film in light-tight
cassettes with two intensifying screens at -70 0 C for 1-6 days [288].
REAGENTS
1. Sonicated salmon sperm DNA: denatured by heating at 95-100°C for 10
min, followed by chilling on ice for 5 min.
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20X SSPE: contains 3M NaCl (BDH), 0.2M NaH2PO4.H2O(BDH), and2.
20 mM EDTA (Sigma) pH value was adjusted to 7.4 with 1 N NaOH.
100% Deionized fonnamide: prepared by stirring 100 ml of formamide3.
(Sigma) and 4 g of Amberlite MB-1 (Sigma) for one and a half hour in
a dark bottle. After removing the ion-exchange resin by filtration through
Whatman No.1 paper, it was stored at -20°C.
4, 1OOXDenhardt's solution: contains 20 mg/ml polyvinyl pyrollidone (Sigma),
20 mg/ml Ficoll-400 (Pharmacia), and 20 mg/ml bovine serum albumin
(Sigma) in autoclaved double distilled water. Sterilized by millipore
filtration.
10% SDS:10 g SDS (Sigma) in 100 ml autoclaved double distilled water.5.
Labelled probe: denatured by heating at 95-100°C for 10 min, followed by6.
chilling on ice for 5 min.
Table 3.1. Features of different HPV DNA probes
a 1611 186(21)'6(A2)HPV
Fragment





Bam H i Bam H I EcoRIEcoRIEcoRlsite
Amp` AmprAmprAmp` Am prGenetic
Tet= TetrTetiTetsTetsmarkers
Host
E. coli HB 101•
organism
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'HPV 6, clone Amp2.
bHPV 6, clone 21.
Table 3.2. Features of different EBV DNA probes
H K WBamHI fragment
Fragment size
6.1 5.1 3.2(Kb)
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Table 3.3. Histologic diagnosis of the bronchogenic carcinomas of Hong









Adenocarcinoma/ Poor Autopsy70FBC 4
SurgicalSquamous cell71MBC 5
carcinoma/ Poor
Adenocarcinoma/ Poor Surgical34MBC 6
Adenocarcinoma/ Poor Surgical68MBC 7
Adenocarcinoma/ Poor Autopsy68FBC 8
AutopsySquamous cell70MBC 9
carcinoma/ Well
AutopsySmall cell carcinoma80FBC 10
Adenocarcinoma/ Well Surgical67FBC 11
Adenocarcinoma/ Well Surgical58MBC 12
RemarksHistologic Diagnosis/Sex AgeSample
Differentiation
Adenocarcinoma/ Poor Surgical57FBC 13
Adenocarcinoma/ Well SurgicalMBC 14
SurgicalAdenocarcinoma,65M'BC 15
Moderate
'64 Adenocarcinoma/ Well SurgicalMBC 16
SurgicalSquamous cellMBC 17
carcinoma/ Moderate
Adenocarcinoma/ Well Surgical43MBC 18
Adenocarcinoma/ Well Surgical60FBC 19
Adenocarcinoma/ Well Surgical63MBC 20


















Table 3.4. Histologic diagnosis of the cervical tissue specimens of Hong
Kong Chinese patients (n= 18)
Histologic DiagnosisAgeSample
Squamous cell carcinomacx 1
Squamous cell carcinoma55Cx 2
Squamous cell carcinoma56CX 3
Squamous cell carcinoma70CX 4
Squamous cell carcinoma53CX 5
Squamous cell carcinoma68CX 6
Squamous cell carcinoma71CX 7
Squamous cell carcinoma48CX 8




Squamous cell carcinoma82CX 13
Histologic DiagnosisAgeSample
Squamous cell carcinoma44CX 14
Squamous cell carcinoma70CX 15
CIN grade II31CX 16
Normal epithelium49CX 17
Normal epithelium35CX 18
Table 3.5. Composition of LB agar
(OXO i D) 10 gTryptone
(OXOI D)Yeast Extract 5 g
Sodium ChloridE 10 g(BDH)
1 litreDistilled Water
Agar 12 g(OXOID)
Adjust pH to 7.5 with 1 M NaOH
Autoclave
Table 3.6. Composition of LB broth
(OXO I D)Tryptone 10 g
(OXO I D)Yeast extract 5 g
Sodium Chloride 10 g(BDH)
1 litreDistilled water
Adjust pH to 7.5 with 1 M NaOH
Autoclave
Table 3.7. Stringency washing conditions for HPV studies
(dot blot)







Table 3.8. Stringency washing conditions for HPV studies
(Southern blot)
Duration Washing timesTemperatureWashing Solution
(min)(°C)
Rr 1302X SSC
50 1402X SSC/0.1 SDS
50 21X SSC/0.1% SDS 30
1500.5X SSC/0.1% SDS 30
1RT 200.5X SSC
'RT: room temperature
Table 3.9. Stringency washing conditions for EBV studies
(Southern blot)








Fig. 3.1. Monolayer cell growth of the human cervical carcinoma cell line CC3, at passage 41.
Fig. 3.2.,' Xenograft developed in athymic nude mouse on the 42th day by the inoculation of
1.7x10' cells.
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Fig. 3.4. The Pstl Cleavage pattern of human papillomavirus tyce 16 DNA (linearlzed over BamHl) and the corresponding open
reading frames (Parkkinen, S., 1988, [289]).
sample template with






-tubing and flow valve
Fig. 3.5. Diagram showing the proper method to assemble the Bio-Dot apparatus (adopted











Fig. 3.6. Diagrammatic representation of Southern blotting. 20X SSC Is drawn up through the gel and deposits the DNA onto





4.1 Growth of transformants
The DNA probes employed in this study were obtained as inserts in the
plasmid vector pBR 322. Plasmids with Col El replicon-like replication origins
such as pBR 322 can be amplified by chloramphenicol treatment [282]. However,
as chloramphenicol stops bacterial cell growth through the inhibition of
prokaryotic protein synthesis, the antibiotics is preferably applied to the bacterial
culture at late logarithmic phase.
In order to monitor the timing of chloramphenicol treatment, the growth
curves of transformants were determined in terms of culture turbidity measured
with Klett-Summerson photoelectric colorimeter. It was found that the growth
of E. coli strain HB101 containing plasmids with HPV 16 and HPV 18
respectively is similar, as expected (Fig. 4.1A and Fig. 4.1B). The logarithmic
phase begins about two hours after inoculation, and reaches stationary phase ten
hours later. The timing of chloramphenicol treatment was estimated to be about
eight hours on incubation at 37° C. About five hundred micrograms of plasmid
DNA can be obtained from 1 litre of overnight batch culture.
4.2 Specificity of Southern blot analysis of HPV DNA
It is well documented that different types of HPV is able to cross-
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hybridize with each other under different hybridization conditions [291, 292].
The specificity of Southern blot hybridization for the detection of HPV DNA in
this study was determined by the hybridization of HPV 16 or HPV 18 DNA
probe with known amounts of linear HPV 6, HPV 11, HPV 16, and HPV 18
DNA released from the plasmid vectors by digestion with appropriate restriction
enzymes. Figure 4.2 indicates that under. the hybridization and washing
conditions in the present study, cross-hybridization of heterologous HPV DNA
was not observed when 0.65 ng (1.ng, together with pBR 322) homologous HPV
DNA shows a strong signal. The same result was obtained when 3.24 ng (5 ng,
together with pBR 322) HPV DNA samples were hybridized with HPV 16 DNA
probe. Moreover, no signal was detected for the plasmid vector pBR 322
indicating that the purity of the HPV 16 and HPV 18 probes was acceptable,
and the signals detected in the positive cases actually reflect the presence of
HPV DNA.
4.3 Sensitivity of EBV DNA detection
The sensitivity of the Southern blot hybridization for*the detection of EBV
DNA was determined. A mixture of labelled BamHI -H, -K, and -W fragments
of EBV strain B95-8, was hybridized to decreasing amounts of cellular DNA
extracted from the Raji cell line (Fig. 4.3). Under the hybridization and washing
conditions in this study, the lower limit of detection was demonstrated to be 0.01
µg Raji cell DNA. Longer exposure of the autoradiograph did not result in
increased sensitivity. As 5 µg cellular DNA can be isolated from 1x106 Raji
cells [293], and each Raji cell harbors about 50 copies of EBV genomic DNA
[276, 294], the detection level was calculated to be 0.05 EBV genomes per cell
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if 10 µg of DNA sample was applied in hybridization assay.
4.4 Sensitivity of HPV DNA detection
The sensitivity of Southern blot hybridization for the detection of
homologous HPV DNA was also determined. Various amounts of HPV16-pBR
322 DNA were mixed with 10,4g of 3T3 DNA and digested with BamHI. The
released HPV 16 DNA, plasmid vector pBR 322, and the digested 3n DNA
were then co-transferred onto nitrocellulose filter after electrophoresis through
0.8% agarose gel. The baked filter was hybridized with labelled HPV 16 DNA
probe and washed as described in Section 3.8. By taking the size of BPV 16
DNA and cellular DNA in a diploid cell to be 7.9 and 3x106 kb respectively
[269, 295], from the result presented in Fig. 4.4, the detection level of
homologous HPV DNA in the present study was calculated to be about 0.625
genome equivalent per diploid cell. No signal was detected for the plasmid
vector pBR 322.
4.5 Analysis of EBV DNA in bronchogenic carcinomas
Tissue samples of bronchogenic carcinomas obtained from 28 Hong Kong
Chinese patients were examined for the presence of EBV DNA by Southern blot
hybridization analysis. In each case, normal tissue of the same patient was as
well collected for comparison. Cellular DNA samples extracted from the tissue
specimens were digested with BamHI, blot transferred onto nitrocellulose filters
and hybridized with a mixture of labelled EBV BamM -H, -K, and -W
fragments. EBV DNA was detected in the cellular DNA from 1 of 7 squamous
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cell carcinomas as well as from 1 of 19 adenocarcinomas (Table 4.1), they are
classified as undifferentiated and poorly differentiated carcinomas respectively.
Moreover, all the non-tumor tissue samples are negative for EBV DNA (Table
4.3).
In one of the positive cases, BC 1, all the three EBV fragments are present
and the signal was found to be stronger than that detected in 5 µg of Raji cell
DNA (Fig. 4.5). Moreover, the EBV BamHI fragment K was demonstrated to
be larger than that in Raji cell DNA. In the other DNA sample probed
positively with EBV, BC 13, a weak single band of about 8.0 kb was detected in
the BamHI-digested DNA (Fig. 4.6). In order to eliminate the possibility of
non-specific binding due to the BamHI-K fragment which has been demonstrated
to be able to hybridize with cellular DNA sequence [296], the experiment was
repeated and the blot was hybridized with labelled BamHI-W fragment. The
same result was obtained (Fig. 4.7). It indicates that EBV DNA is present in the
tumor tissue analyzed.
4.6. Analysis of HPV DNA in bronchogenic carcinomas
The presence of HPV 6/11 DNA was studied by dot blot hybridization
with a mixture of labelled HPV 6 and HPV 11 full genomic DNA probe. No
HPV 6/11 was found in all the 28 cases of bronchogenic carcinomas, including
both the normal and tumor tissues. Some of the results are shown in Fig. 4.8.
The sensitivity of dot blot hybridization for the detection of homologous HPV
DNA was also determined by the hybridization of labelled HPV 11 DNA probe,
to decreasing amounts of HPV 11 DNA. It was found that the detection level
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is about 0.125 genome copy per diploid cell equivalent (Fig. 4.9).
The presence of HPV 16 and HPV 18 in these tissue specimens were as
well analyzed by Southern blot hybridization assay. The prepared blots were
hybridized separately with labelled HPV 16 and HPV 18 DNA probes. No
positive finding was obtained in all the tumor and non-tumor tissue samples.
4.7 Analysis of EBV DNA in cervical cancers
The 18 tissue samples, including 2 normal epithelial tissues, 1 CIN II, and
15 cervical carcinomas were examined for the presence of EBV DNA by
Southern blot hybridization analysis. The DNA samples were digested with
BamHI, blot transferred onto nitrocellulose filters, and hybridized with a mixture
of labelled EBV Barn HI -H, -K, and -W fragments. It was found that all the
DNA samples were negative for EBV DNA.
4.8 Analysis of HPV DNA in cervical cancers
A.. Incidence
By Southern blot hybridization analysis, 11/14 (78.6%) squamous cell
carcinomas were found to have HPV 16 related DNA sequences and 2 others
(14.3%) to have HPV 18 related DNA sequences (Table 4.2, 4.4). The DNA
samples obtained from the two normal epithelial tissues, one CIN II, and one
adenocarcinoma did not have either of these HPV DNA sequences. Moreover,
none of the 18 cervical tissue specimens was found to have DNA sequencec.
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related to HPV 6 and HPV 11. The intensities of bands hybridized with the
HPV probes varied in different samples indicating varied copy number of HPV
DNA in the tissue samples.
B. Physical state of HPV DNA
The restriction enzyme EcoRI cuts HPV 18 DNA once producing a full-
length linear molecule. Of the two EcoRI-digested tumor DNA samples probed
positively with HPV 18 DNA, one showed a single band co-migrated with the
linear form (F III) (Fig. 4.19), suggesting that in this tumor only free episomal
viral DNA is present. In the second case, a single band smaller than 7.9 kb was
detected (Fig. 4.20), suggestive either of episomal viral DNA or integration of
deleted HPV genome.
The state of HPV 16 related DNA sequence in squamous cell carcinomas
was analyzed after the cleavage of tumor DNA with BamHI which cuts the viral
DNA once producing a full-length linear molecule (F III), or PstI which cuts the
viral genome at six different sites, as well as some other restriction enzymes
such as HindfII, XbaI, -Sad, and BglI which have no cleavage site within the
HPV 16 genome. If only episomal viral DNA sequence is present, the BamHI
and Pstl treatment will produce 2.82, 1.78, 1.06, 0.91, 0.64, 0.48, and 0.22 kb
fragments characteristic to the HPV 16 genome [2971. However, the 0.22 kb
fragment is usually not detected because it often runs off the gel. In contrast,
if there exists integration of the viral DNA into cellular genome, extra bands of
lower intensity in addition to all or some of the BarHI/PstI fragments will be
demonstrated. These bands may probably represent HPV-cellular DNA
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integration junction fragments. By using DNA fragments obtained from the
cleavage of cloned HPV 16 DNA with BamHI and PstI as reference, the
presence of full genomic HPV 16 DNA was confirmed in the majority of the
cervical carcinomas (Fig. 4.22).
Moreover, if Southern blot hybridization analysis of the tumor DNA
digested with no-cut enzymes revealed the existence of linear form (F III) and/or
relaxed circular form (F II) as well as supercoiled form (F I) of the viral genome,
it could be possible that HPV 16 DNA is present in episomal form, either
monomeric or oligomeric. On the other. hand,,:the detection of high-molecular-
weight bands which can be mobilized by cutting with different no-cut enzymes
is suggestive of the presence of integrated viral DNA sequence. Bands of
different sizes are produced as the flanking cellular DNA sequences were
cleaved into different lengths. However, if the HPV-cellular DNA integration
fragments are very large, the difference in size may not be resolved in gel
electrophoresis. Based on the above interpretation, both integrated and
episomal HPV DNA sequences were found in the cervical tumor specimens.
Nevertheless, complex integration pattern and possibly 'subgenomic deletion
and/or amplification will make the interpretation ambiguous.
In CX 1, two types of tissue samples were obtained. Both of them were
histologically confirmed to be cervical carcinoma. However, in contrast to the
abnormal macroscopic appearance of CX 1T, CX 1N appeared to be normal
during colposcopic examination. From the analysis of the DNA samples
extracted from them, it was found that both of them have integrated HPV DNA
in which the intensity of positive signal in CX 1T is stronger than CX 1N.
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Integrated HPV genome was also demonstrated in CX 3, CX 6, CX 8, CX
9, and CX 15. In CX 9, as a single band slightly smaller than 7.9 kb was
detected in the BamHI-digested tumor DNA, full-length viral genome seems to
have integrated into the cellular DNA sequence near the single BamHI site of
HPV 16 (Fig. 4.18). The extra bands observed in addition to all the BamHI/PstI
fragments of the prototype HPV DNA may represent HPV-cellular DNA
integration fragments. Moreover, since no more than two junction fragments
were found in this sample, the HPV integration had probably occurred at a
single site. As for CX 3 and CX 15, viral DNA integration was suggested as the
bands (greater than 7.9 kb) can be mobilized by treating the DNA samples with
different no-cut enzymes (Fig. 4.12). In CX 6 and CX 8, the PstI cleavage
pattern was found to be significantly different from that of the cloned HPV 16
DNA, which demonstrates either of a complex integration pattern or the
presence of unknown HPV types closely related to HPV 16 (Fig. 4.15 and 4.17).
Digestion of the tumor. DNA extracted from CX 4 with BamHI revealed
a single band co-migrated with the linear form (F III) of HPV 16 DNA (Fig.
4.13). When analyzed with no-cut enzymes, viral DNA molecules in forms _F I,
F II, and F III were detected. The presence of only episomal monomers was
further confirmed by cutting the DNA sample with Barn HI and PstI which
showed all the f ragments of the prototype HPV 16 DNA.
Southern blot hybridization analysis of the last four DNA samples that
probed positively with HPV 16 DNA revealed the presence of episomal viral
DNA sequences (Fig. 4.11, 4.14, 4.16, 4.21). Linear form (F III), relaxed circular
form (F II) and supercoiled form (F I) of monomeric viral DNA molecules were
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detected in the cellular DNA digested with different no-cut enzymes. In CX 5,
the- prominent bands indicated by arrow heads in Fig.4.14 B, which were not
mobilized by cutting with different no-cut enzymes, may represent the different
conformations of episomal oligomers (most possibly dimers). Moreover, the two
bands with very high molecular weight is suggestive of integrated HPV DNA in
the host genome. As no extra band was detected in the BamH/PstI-digested
DNA sample, the full-length viral genome may exist as multimeric tandem
repeats or as monomers integrated into cellular DNA near the single BamHI
site in HPV 16.
In the other three tissue specimens (CX 2, CX 7, CX 14), in addition to
the different conformations of episomal viral monomers, a single band with very
high molecular weight was detected in the DNA samples digested with different
no-cut enzymes (Fig. 4.11, 4.16, 4.21), suggesting that HPV DNA has also been
integrated into the host genome. It is unlikely that this high-molecular-weight
band represents episomal oligomer because of its large size and the lack of any
other oligomeric DNA conformations. The integrated viral DNA in these tissue
specimens seems to be either a multimeric tandem repeat of the whole genome,
or a monomeric full genomic viral DNA integrated near the single BamHI site.
To conclude, in the eleven cervical squamous cell carcinomas that harbor
HPV 16 related DNA sequences, one tissue specimen (9.1%) contained HPV
in episomal form, and six others (54.5%) in cellular DNA-integrated form. The
simultaneous presence of both episomal and integrated forms was found in the
remaining four positive tissue samples (36.4%).
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4.9 Analysis of HPV DNA in CO and xenografts
Southern blot hybridization analysis of the DNA extracted from the
cervical cancer cell line CC3 and the xenografts derived from it revealed the
presence of only HPV 16 related DNA sequences (Table 4.6). The detection of
two bands in the BamHI-digested CC3 DNA sample and three high-molecular-
weight bands when analyzed with HindiIl are highly suggestive of integrated
form of HPV DNA in the CC3 genome (Fig. 4.23). Furthermore, the viral DNA
was found to be deleted and rearranged since only three BamHIlPstI fragments
with sizes different from that of the prototype HPV 16 DNA were found. When
the CC3 DNA was further analyzed by cutting with another no-cut enzyme for
HPV 16 DNA, XbaI, a single band of about 7.9 kb was detected (Fig. 4.23 B).
By considering with the result obtained from HindfII treatment, it was suggested
that the altered HPV DNA, together with its flanking cellular sequence, exists
as repeated units of DNA sequence integrated into the CC3 genome at multiple
sites as single copy or head-to-tail tandem repeats. One Mal cleavage site was
expected to exist on the flanking host genomic DNA on each side of the viral
.genome. In order to determine the complex integration pattern of HPV in-this
cell line, further.'studies should be conducted.
From the analysis of the DNA samples extracted from the nude mouse
xenografts, it was demonstrated that the viral DNA sequence exists in the same
pattern as in CO (Fig. 4.24 A). However, analysis of the HindiI-digested DNA
samples isolated from both the xenografts (passage 0 and passage 1) revealed
the lost of a band as compared with the cell line (Fig. 4.24 B). It implies that
rearrangement or deletion had occurred in the nude mouse xenografts.
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The deleted and rearranged HPV DNA in CO and the nude mouse
xenografts was further analyzed by Southern blot hybridization with labelled
BamHI/PstI subgenomic fragments of HPV 16. By naming the BamHI/PstI
fragments detected in the cellular DNA samples as fragment 1, 2, and 3 in
descending order of sizes, it was found that the subgenomic fragment A probes
positively with both fragment 1 and fragment 3 (Fig. 4.25 A), suggesting that the
HPV DNA may open within the subgenomic fragment A during integration,
possibly accompanied with sequence deletion. As for subgenomic fragments B
and D, they probe positively with fragment 3 and fragment 2 respectively (Fig.
4.25 B, 4.26 D). The difference in size observed between the prototype' ETV 16
DNA and the cellular DNA suggestive of deletion and rearrangement. Finally,
the BamHI/PstI-digested DNA samples showed weak signals of fragment 1 when
hybridized with subgenomic fragment C and F, suggesting that a considerable
portion of these fragments may be deleted during or subsequent to the viral
integration events (Fig. 4.26 C, 4.26 F). Preliminary study found that the
subgenomic fragment E probe positively with fragment 2 (data not shown), which
further supports that the HPV DNA opens within fragment A during integration,
since it is the only probe simultaneously hybridized with two BamHI /PstI
fragments of CO cellular DNA.
Table 4.1. Presence of EBV DNA in the bronchogenic carcinomas of Hong












Table 4.2. Presence of HPV DNA in the cervical tissue samples of Hong
Kong Chinese patients (n'=,18)
Presence of HPV relatedHistologic
DNA sequencesdiagnosis







Table 4.3. Presence of EBV DNA in the broncnogenic carcinomas ana normal
bronchial tissues of Honc Kong Chinese patients (n= 28)
EBV BamHI-Histological Diagnosis/Sample
H K WDifferentiation













BC 5N Normal parenchyma
Squamous cell5T
carcinoma/ Poor
BC 6N Normal parenchyma
Adenocarcinoma/ Poor6T
EBV BamHI-Histological Diagnosis/" Sample
H K WDifferentiation
BC 7N Normal parenchyma
Adenocarcinoma/ Poor7T
BC 8N Normal parenchyma
Adenocarcinoma/ Poor8T








BC 12N Normal parenchyma
Adenocarcinoma/ Well12T
BC 13N Normal parenchyma
Adenocarcinoma/ Poor N N13T




BC 15N Normal parenchyma
Adenocarcinoma/15T
Moderate
BC 16N Normal parenchyma
Adenocarcinoma/ Well16T
BC 17N Normal parenchyma
Squamous cell17T
carcinoma/ Moderate
BC 18N Normal parenchyma
Adenocarcinoma/ Well18T
BC 19N Normal parenchyma
Adenocarcinoma/ Well19T
BC 20N Normal parenchyma
Adenocarcinoma/ Well20T
BC 21N Normal parenchyma
Large cell carcinoma/21T
Undifferentiated





BC 23N Normal parenchyma
Adenocarcinoma/23T
Moderate
BC 24N Normal parenchyma
Squamous cell24T
carcinoma/ Well
BC 25N Normal parenchyma
\denocarcinoma/'25T
Moderate
BC 26N Normal parenchyma
Squamous cell26T
carcinoma/ Poor
BC 27N Normal parenchyma
Adenocarcinoma/27T
Moderate





Table 4.4 Presence of HPV DNA in the cervical tissue specimens of Hong
Kona Chinese patients (n= 18)
HPV DNA
6 11 16 18Histological DiagnosisSample
Squamous cell carcinomaCX 1
Squamous cell carcinomaCX 2
Squamous cell carcinomaCX 3
Squamous cell carcinomaCX 4
Squamous cell carcinomaCX 5
Squamous cell carcinomaCX 6
Squamous cell carcinomaCX 7
Squamous cell carcinomaCX 8
Squamous cell carcinomaCX 9
Squamous cell carcinomaCX 10
Squamous cell carcinomaCX-11
AdenocarcinomaCX 12
Squamous cell carcinomaCX 13
HPV DNA
6 11 16 18Histological DiagnosisSample
Squamous cell carcinomaCX 14
Squamous cell carcinomaCX 15
CIN grade IICX 16
Normal epitheliumCX 17
Normal epitheliumCX 18
presence of DNA sequence related to the indicated HPV
type
absence of DNA sequence related to the indicated HPV
type
Table 4.5 Physical state of HPV 16 related DNA sequence in the cervical
tissue specimens of Hong Kong Chinese patients (n= 11)
HPV 16 related DNA
sequence
IntegratedEpisomalHistological DiagnosisSamnlP
Squamous cell carcinomaCX 1
Squamous cell carcinomaCX 2
Squamous cell carcinomaCX 3
Squamous cell carcinomaCX 4
Squamous cell carcinomaCX 5
Squamous cell carcinomaCX 6
Squamous cell carcinomaCX 7
Squamous cell carcinomaCX 8
Squamous cell carcinomaCX 9
Squamous cell carcinomaCX 14
Squamous cell carcinomaCX 15
absencepresence
Table 4.6. HPV DNA in the cervical cancer cell line CC3 and the nude mouse
xenografts derived from it







presence of DNA sequence reiateu LU LJ1 111U1GcLLCU nr V
type
absence of DNA sequence related to the indicated HPV
type
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FIG. 4.2. Hybridization of labelled HPV 16 or HPV 18 probe to HPV genomic DNA freed from
the cloning vector by treating with the appropriate restriction enzymes. A. Lanes 1 to 4:1 ng
of HPV 6 (clone 21 plus clone Amp 2), HPV 11, HPV 16, and HPV 18 plasmid respectively
hybridized with labelled HPV 16 probe. B. Lanes 1 to 4: 1 ng of HPV 18, HPV 16, HPV 11, and
HPV 6 plasmid respectively hybridized with labelled HPV 18 probe. C. Lanes 1 to 4:, 5,ng of
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FIG. 4.3. Sensitivity of detection of EBV DNA. Various dilutions of Raji cellular DNA were cleaved with Barn HI and hybridized to labelled EBV
BamHl-H, -K, and -W fragments. In A and B, lanes 1 to 4: 2.5, 1.0, 0.5, 0.25 pg Raj! DNA respectively. In B, lane 5: 0.05 pg Raji DNA. In C,
lanes 1 to 4: 100, 50, 25, and 10 ng Raji DNA respectively. A: one day exposure B and C: three days exposure.










FIG. 4.4. Sensitivity of detection of HPV DNA. Various amounts of HPV 16 plasmid were each mixed with 10 ILg of BALB/c 3T3 DNA and
cleaved with BarHl. The digested 3T3 DNA and HPV 16 plasmid were subjected to electrophoresis, co-transferred onto nitrocellulose filter and
hybridized with labelled HPV 16 DNA probe. In A and B, lanes 1 to 6: 25, 12.5, 6.25, 2.5, 1.25, and 0.625 copies of HPV 16 DNA per diploid cell
respectively lane 7: 10 $g of BamHI-digested 3T3 DNA. A: 1 day exposure. B: 3 days exposure.




FIG. 4.5. Hybridization of BamHl-cleaved cedular DNAs extracted from lung tissue sampless
with labelled EBV BamH-H, -K, and -W fragments
Lane 1: 5ug Raji DNA
Lane 4: 10ug BC 4T DNA
Lane 7: 10ug BC 5N DNA
Lane 10: 10ug BC 26N DNA
Lane 2: 10ug BC 1T DNA
Lane 5: 10ug BC 4N DNA
Lane 8: 10ug BC 21N DNA
Lane 11: 10ug BC 26T DNA
Lane 3: 10ug BC 1N DNA
Lane 6: 10ug BC 5T DNA
Lane 9: 10ug BC 21T DNA
Lane 12: 10ug hunan cord
blood lymphocyte
DNA
Molecular weight markers indlicated on the right of the biot are Hindill fragments of phage
ambda DNA with the following sizes: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 kb.




FIG. 4.6. Hybridization of BamHl-cleaved DNA samples extracted from lung tissue
specimens with labelled EBV BamHl-H,-K,and -W fragments.
Lane 1: 5 ug Raji DNA Lane 2: 10 ug BC 1N DNA Lane 3: 10 ug BC 1T DNA
Lane 4: 10 ug BC 26T DNA Lane 5: 10 ug BC 26N DNA Lane 6: 10 ug BC 13T DNA
Lane 7: 10 ug BC 13N DNA Lane 8: 10 ug BC 24T DNA Lane 9: 10 ug BC 24N DNA
Molecular welght markers Indicated on the right of the blot are Hindll fragments of phage
lambda DNA with the following sizes: from top. 23, 9.4,6.5,4.3,2.3, and 2.0 kb
1 2 3 4 5 6 7 8 9 10 11 12 13
EBV- W
3.2 kb
FIG. 4.7. Hybridization of BamHI-cleaved DNA samples extracted from lung tissue
specimens with labelled EBV BamHl-W fragment.
Lane 3: 10 µg BALB/c 3T3Lane 2: 5 µg Raji DNALane 1: 10 µg Raji DNA
DNA
Lane 6: 10,ug BC 22N DNALane 5: 10 µg BC 13T DNALane 4: 10µg BC 13N DNA
Lane 9: 10 ,cg BC 26T DNALane 8: 10 µg BC 26N DNALane 7: 10 µg BC 22T DNA
Lane 12: 10 Lg human cordLane 11: 10 µg BC 24T DNALane 10: 10 µg BC 24N DNA
blood lymphocyte
DNA
t.Lane,13: 10 µg Rail DNA
Molecular weight markers indicated on the right of the blot are Hindlll fragments of phage
Iam MIA with the following sizes: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
1 2 3 4 5 6 7 8 9 10 11 12
FIG: 4.8. Nucleic acid dot hybridization of DNA samples extracted from lung tissue
specimens with labelled HPV 6 (clone 21 plus clone Amp2) and HPV 11 DNA probes.
Row 2: 0.5 ngRow 1: 1 ng
Column 2: HPV 11Column 1: HPV 6
Row 2: 2 ugRow 1: 10µg
Column 4: BC 1T Column 5: BC 1 NColumn 3: BALB/c 3T3
Column 7: BC 2N Column 8: BC 2BColumn 6: BC 2T
Column 10: BC 5N Column 11: BC 6TColumn 9: BC 5T
Column 12: BC 6N
1 2 3 4 5 6 7
1
2
F.M. r4.9. Sensitivity of detection of HPV DNA in dot hybridization.
Row 1: HPV 11 DNA
Column 3: 6.25 gcColumn 2: 12.5 gcColumn 1: 25 gc
Column 6: 0.25 gcColumn 5:1.25 gcColumn 4: 2.5 gc
where gc= genome copy/diploid cell equivalent
Column 7: 0.125 gc
Row 2: BALB/c 3T3 DNA
Column 3: 2 ugColumn 2: 5,cgColumn 1: 10 µg
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FIG. 4.10. Southern blot analysis of DNA extracted from CX 1. Samples of 10 pg of DNA
were digested with various enzymes and hybridized with labelled HPV 16 probe.
A.Lanes 1 and 2: CX 1 N and CX 1 T cleaved with BamHl respectively
B.Lane 1: linearized full genomic HPV 16 DNA (1 ng)
Lanes 2 and 3: CX 1N cleaved with Hindill and Xbal respectively
Lanes 4 and 5: CX 1T cleaved with Hindlll and Xbal respectively
C.Lanes 1 to 3: HPV 16 (3 ng), CX 1N, and CX 1T cleaved with BamHl /Pstl respectively.
Arrow heads represent BamHI/Pstl restriction fragments of HPV 16 DNA with the following
sizes: from top, 2.82, 1.78, 1.06, 0.91, 0.64, and 0.48 Kb. Arrows indicate extra bands which
mav be virus-cell function DNA fragments.
This figure is a composite of several autoradiographs. The bars on the left of each blot are size
markers: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
A B C
1 2 3






FIG.4.11. Southern blot hybridization analysis of the DNA extracted from CX 2 with labelled
HPV 16 probe.
A. Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10ug BALB/c 3T3 DNA digested with BamHI
Lane 3: 10 ug CX 2 DNA digested with BamHI
The bars on the left of the blot Indicate the positions of phage lambda-Hindlll DNA marker
fragments: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
B. Each lane contains 10 jug CX 2 DNA digested respectively with various enzymes. Lane 1:
Hindlll lane 2: Xbal lane 3: Bg/l lane 4: Sacl.
C. Lanes 1, 2, and 3 contain 3 ng HPV 16 DNA, 10µg BALB/c 313 DNA, and l0 µg CX 2 DNA
digested respectively with BamHl/Pstl.
The bars on the left of the blot indicate the positions of BamHl /Pstl restriction fragments of
HPV 16 DNA with the following sizes: from top, 2.82, 1.78, 1.06, 0.91, 0.64, and 0.48 Kb.
A B
1 2 3 4 5 1 2 3 4 5 6
FIG.. 4.12. Southern blot hybridization analysis of the DNA samples extracted from CX 3 and
CX 15 with labelled HPV 16 DNA probe.
A. Lane 1: 1 ng linear HPV 18 DNA
Lane 2: 1 ng linear HPV 16 DNA
Lane 3: 10µg BALB/c 3T3 DNA digested with BamHl
Lane 4: 10 µg CX 3 DNA digested with BamHl
Lane 5: 10 µg CX 15 DNA digested with BamHI
B. Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 ug BALB/c 3T3 DNA digested with BamHl
Lane 3: 10ug CX 3 DNA digested with Hindlll
Lane 4: 10 ug CX 3 DNA digested with Sacl
L4ne.5: 10 ug CX 15 DNA digested with Hindlll
Lane 6: 10 ug CX 15 DNA digested with Saci
The positions of phage lambda-Hindlll DNA marker fragments are indicated on the left of each
blot: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
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FIG. 4.13. Southern blot hybridization analysis of the DNA sample extracted from CX 4 with
labelled HPV 16 DNA probe.
A. :Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 µg CX 4 DNA digested with BamHl
'Lane 3: 10 ug CX 5 DNA digested with BamHl
.Lane 4: 10 cg BALB/c 3T3 DNA digested with BamHl
B. Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 µg BALB/c 3T3 DNA digested with EcoRl
Lane 3: 10 Lg CX 4 DNA digested with Hindill
Thp,hars nn the Ieft of each blot are size markers: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
C. Lanes 1, 2, and 3 represent HPV 16 DNA (3 ng), 10 ug BALB/c 3T3 DNA, and 10 ug CX 4
DNA digested respectively with BamHl/Pstl.
BA C












FIG. 4.14. Southern blot hybridization analysis of the DNA sample extracted from CX 5 with
labelled HPV 16 DNA probe.
A.Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10ug CX 4 DNA digested with BamHI
Lane 3: 10 ug CX 5 DNA digested with BamHl
Lane 4: 10 ug BALB/c 3T3 DNA digested with BamHI
B. Each lane contains CX 5 DNA (10 ug) cleaved with various restriction enzymes.
Lane 1: 1 ng linear HPV 16 DNA
Lane 2: Hindlll Lane 3: Xbal Lane 4: Bg1I
The bars on the left of each blot are size markers: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 kb
C. Lane 1: 3 ng HPV 16 DNA cleaved with BamHl/Pstl
Lane 2: 10 ug BALB/c 3T3 DNA cleaved with BamHl/Pstl
Lane 3: 10 ug CX 5 DNA cleaved with BamHl/Pstl
A B C
1 2 3 1 2 1 2 3
FIG. 4.15. Southern blot hybridization analysis of the DNA sample extracted from CX 6 with
labelled HPV 16 DNA probe.
A. Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 µg BALB/c 3T3 DNA digested with BamHl
Lane 3: 10µg CX 6 DNA digested with BamHI
B. Lane 1: 10 µg CX 6 DNA digested with Hindlll
Lane 2: 10 µg CX 6 DNA digested with Xbal
The positions of phage lambda-Hindlll DNA marker fragments are indicated on the left of each
blot from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
C.Lane 1: 3 ng HPV 16 DNA cleaved with BamHl/Pstl
Lane 2: 10 ug BALB/c 3T3 DNA cleaved with BamHl/Pst
Lane 3: 10 ug CX 6 DNA cleaved with BamHI/Pstl
The bars on the left of the blot represent the positions of BamHI/Psti restriction enzyme
















FIG. 4.16. Southern blot hybridization analysis of the DNA sample extracted from CX 7 with
labelled HPV 16 DNA probe.
A. Lane 1: 1 ng linear HPV 18 DNA
Lane 2: 1 ng linear HPV 16 DNA
Lane 3: 10 ug BALB/c 3T3 DNA digested with BamHl
Lane 4: 10 ug CX 7 DNA digested with BamHl
B. Lane 1: 1 ng linear HPV 16 DNA
Lanes 2 to 4: each lane contains 10µg CX 7 DNA digested respectively with Hindlll, Xbal,
and Bg/l
The bars on the left of each blot indicate the positions of phage lambda-Hindlil DNA marker
fragments: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
C. Lane 1: 3 ng HPV 16 DNA cleaved with BamHl/Pstl
Lane ,2: 10 ug CX 7 DNA cleaved with BamHI /Pstl
A B C








FIG. 4.17. Southern blot hybridization analysis of the DNA sample extracted from CX 8 with
labelled HPV 16 DNA probe.
A. Lane 1: 1 ng linear HPV 18 DNA
Lane 2: 1 ng linear HPV 16 DNA
Lane 3: 10 ug CX 8 DNA digested with BamHI
Lane 4: 10,ug CX 8 DNA digested with Hindlll
B. Lane 1: 10 ug CX 8 DNA digested with HindIll
Lane 2: 10ug CX 8 DNA digested with Xbal
The bars on the left of each blot indicate the positions of phage lambda-Hindlil DNA marker
fragments: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
C. Lanes 1 to 3 represent 3 ng HPV 16 DNA, 10 ug BALB/c 3T3 DNA, and 10 ug CX 8 DNA
digested. respectively with BamHI/Pstl.
Arrowsi indicate the positions of faint bands.
A B C
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FIG. 4.18. Southern blot hybridization analysis of the DNA sample extracted from CX 9 with
labelled HPV 16 DNA probe.
Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 µg CX 9 DNA digested with BamHl
Lane 3: 10 µg CX 10 DNA digested with BamHl
rat Lane 4: 10 µg CX 11 DNA digested with BamHI
Blane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 ILg CX 9 DNA digested with Hindlll
Lane 3: 10 µg CX 9 DNA digested with Xbal
The bars on the left of each blot indicate the positions of phage lambda-Hindlll DNA marker
Fragments:from top, 23, 9.4,6.5, 4.3, 2.3, and 2.0 kb
C. Lane 1: 3 ng HPV 16 DNA cleaved with BamHI /Psti
Lane 2: 10µg BALB/c 3T3 DNA cleaved with BamHl/Pstl
Lane 3: 10 µg CX 9 DNA cleaved with BamHl/Pstl
Arrow heads represent BamHl/Pstl restriction fragments of HPV 16 DNA with the following
sizes: from top, 2.82, 1.78, 1.06, 0.91, 0.64, and 0.48 Kb. Arrows indicate extra bands which
may be virus-cell junction DNA fragments.
1 2 3 4
HPV 18
FIG. 4.19. Southern blot hybridization analysis of the DNA samples extracted from cervical
tissue specimens with labelled HPV 18 DNA probe.
Lane 1: 1 ng linear HPV 18 DNA
Lane 2: 10 ug CX 9 DNA digested with EcoRl
Lane 3: 10ug CX 10 DNA digested with EcoRl
Lane 4: 10 ug CX 11 DNA digested with EcoRI
Molecular weight markers indicated on the right of the blot are HindIll fragments of phage
lambda DNA with the following sizes: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
1 2 3 4 5 6 7
FIG. 4.20. Cellular DNAs extracted from cervical tissue samples were digested with EcoRl
and analyzed by Southern blot hybridization with labelled HPV 18 DNA probe.
Lane 1: 1 ng linear HPV 16 DNA Lane 2: 1 ng linear HPV 18 DNA
Lane 3: 10 ug CX 18 DNA Lane 4: 10 ugCX17DNA
Lane 5: 10 ug CX 16 DNA Lane 6: 10 ug CX 13 DNA
Lane 7: 10 ug BALB/c 3T3 DNA
The arrow on the right of the blot Indicates the position where a faint band was detected in
the lane containing the DNA sample extracted from CX 13.
The bars on the left of the blot Indicate the positions of phage lambda-Hindlll DNA marker
fragments: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
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FIG. 4.21. Southern blot hybridization analysis of the DNA sample extracted from CX 14 with
labelled HPV 16 DNA probe.
A. Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 ug BALB/c 3T3 DNA digested with BamHI
Lane 3: 10 ug CX 14 DNA digested with BamHl
B. Lane 1: 1 ng linear HPV 16 DNA
Lanes 2 to 4: each lane contains 10 gg CX 14 DNA digested respectively with Hindlll, Xbal,
and Bg/l
The bars on the left of each blot Indicate the positions of phage lambda-Hindlll DNA marker
fragments: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
C. Lanes 1, 2, and 3 represent HPV 16 DNA (3 ng), 10µg BALB/c 3T3 DNA, and 10 µg CX 14
DNA digested respectively with BamHl /Pstl.
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FIG. 4.22. Southern blot hybridization analysis of the DNA samples extracted from cervical
carcinomas with labelled HPV 16 DNA probe.
,Lane 1: 3 ng HPV 16 DNA cleaved with BamHl/Pstl
Lane 2: 10µg BALB/c 3T3 DNA cleaved with BamHl/Pstl
Lanes 3 to 10: each lane contains 10 µg of cellular DNA cleaved with BamHl /Pstl
lane 3: CX 1N lane 4: CX 1T lane 5: CX 2
lane 6: CX 4 lane 7: CX 5 lane 8: CX 7
lane 9: CX 9 lane 10: CX 14
The bars on the left of the blot Indicate the positions of the BamHI/Pstl restriction fragments
of HPV 16 DNA with the following sizes: from top, 2.82, 1.78, 1.06, 0.91, 0.64, and 0.48 Kb.
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B








FIG. 4.23. Southern blot hybridization analysis of the DNA sample extracted from the
cervical cancer cell line CC3 with labelled HPV 16 DNA probe.
A. Lane 1: 1 ng linear HPV 16 DNA
Lanes 2, 3, 6: each lane contains 10µg CC3 DNA digested respectively with BamHl, Hindlll,
and BamHl/Pstl
Lane 4: 3 ng HPV 16 DNA digested with BamHi/Pstl
Lane 5: 10 µg BALB/c 3T3 DNA digested with EcoRI
B. Lane 1: 1 ng linear HPV 16 DNA
Lane 2: 10 µg CC3 DNA diaested with Xbal
The dots on the left of each blot IndIcate the positions of phage lambda-Hindlil DNA marker
fragments: from top, 23, 9.4, 6.5, 4.3, 2.3, and 2.0 Kb.
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B





















FIG.4.24. Southern blot hybridization analysis of the DNA samples extracted from the
cervical cancer cell line CC3, and the nude mouse xenografts derived from it with labelled HPV
16 DNA probe.
A. Lane 1: 1 ng linear HPV 16 DNA
Lanes 2 and 6: each lane contains 10 ug CC3 DNA digested respectively with BamHl and
BamHI /Pstl
Lanes 3 and 7: each lane contains 10 ug CC3PO DNA digested respectively with BamHl and
BamHl /Pstl
Lanes 4 and 8: each lane contains 10 ug CC3P1 DNA digested respectively with BamHl and
BamHl/Pstl
Lane 5: 3 ng HPV 16 DNA digested with BamHl /Pstl
Lane 9: 10 ug BALB/c 3T3 DNA digested with EcoRl
B. Lane 1: 10ug CC3 DNA digested with Hindlll
Lane 2: 10 ug CC3PO DNA digested with Hindlll
Lane 3: 10 ug CC3P1 DNA digested with Hindlll
A B
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FIG. 4.25. Southern blot hybridization analysis of the DNA samples extracted from the
cervical cancer cell line CC3, and the nude mouse xenografts derived from it with labelled HPV
16 subgenomic DNA probes.
A. Lane 1: 2 ng HPV 16 DNA digested with BamHl /Pstl
Lane 2: 10 µg CC3 DNA digested with BamHl/Pstl
Lane 3: 10 µg CC3PO DNA digested with BamHl/Pstl
lane 4: 10 µg CC3P1 DNA digested with BamHl/Pstl
Hybridized with HPV 16 BamHI /Pstl subgenomic DNA fragment A
13. Lane 1: 2 ng HPV 16 DNA digested with BamHI/Pstl
Lane 2: 10 ug CC3 DNA digested with BamHl/Pstl
Lane 3: 10 ug CC3PO DNA digested with BamHl/Pstl
Lane 4: 10 ug CC3P1 DNA digested with BamHl/Psti
Hybridized with HPV 16 BamHI/Psti subgenomic DNA fragment E
C D F
1 2 3 41 2 3 4





FIG. 4.26. Southern blot hybridization analysis of the DNA samples extracted from the
cervical cancer cell line CC3, and the nude mouse xenografts derived from it with labelled HPV
16 subgenomic DNA probes.
In C and F:
Lane 1: 2 ng HPV 16 DNA digested with BamHl /Pstl
Lane 2: 10 µg CC3 DNA digested with BamHI/Pstl
Lane 3: 10 µg CC3PO DNA digested with BamHl/Pstl
Lane 4: 10 µg CC3P1 DNA digested with BamH4/Pstl
C: Hybridized with HPV 16 BamHI/Pstl subgenomic DNA fragment C
F: Hybridized with HPV 16 BamHl/Psti subgenomic DNA fragment F
In D:
Lane 1: 10 ug CC3P1 DNA digested with BamHl/Pstl
Lane 2: 10 ug CC3PO DNA digested with BamHI/Pstl
Lane 3: 10 ug CC3 DNA digested with BamHI/Pstl
Lane 4: 2 ng HPV 16 DNA digested with BamHl/Pstl
Hybridized with HPV 16 BamHl /Pstl subgenomic DNA fragment D
The dots on the right of each blot indicate the positions of phage lambda-Hindlll DNA marker




5.1 Evaluation of Method
In the present study, the DNA probes were all obtained as recombinant
plasmids composed 'of viral inserts cloned respectively in the plasmid vector
pBR 322. As this vector has a Col El-like replication origin, its copy number
in bacterial cells can be amplified by chloramphenicol treatment [282, 298]. From
the growth curve determined for the transformants containing the plasmids
carrying HPV 16 or HPV 18, it showed that chloramphenicol should be applied
to the bacterial batch culture about eight hours after inoculation. This timing
is critical in order to obtain a desirable yield of recombinant plasmids. It was
found that the yield might be reduced to less than 200 µg if the antibiotics was
not avvlied at the annronriate time.
The viral inserts cloned in the.plasmid vectors were released from their
respective cloning sites by the digestion with the appropriate restriction enzymes
(Table 3.1 and 3.2). The probes were then purified by electrophoresis and
electroelution. It has been reported that clinical specimens of various types may
contain DNA with vector homology probably due to bacterial contamination,
and the isolated probes may still contain vector sequence [299]. In this- study,
Southern blot hybridization was employed as the principal method. The sizes
of the hybridizing fragments detected in the DNA samples as well as in the
positive control standards provide an internal check to eliminate any
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false-positive signal.
Random primer extension technique was used to label the DNA probes
with [a 3P]dCTP for the hybridization assays in the present study. It involves
the annealing of hexanucleotide primers to the denatured DNA to be labelled.
The Klenow fragment of DNA polymerase I incorporates the available
radiolabelled and non-radiolabelled nucleotides into the DNA probe utilizing
the single-stranded DNA sequence as template [284, 285]. It has several
advantages over nick translation technique: (1) DNA probes with higher specific
activity can be obtained, usually two- to five-fold greater than the DNA labelled
by nick translation reaction [300, 284] (2) it can be used to label short (100
base pairs or less) DNA fragments (3) DNA probes purified in agarose gels can
be labelled in the presence of gel contaminants or even directly in melted
agarose, in contrast to nick translation in which agarose contaminants inhibit the
reaction probably by interfering with the DNase I nicking step [284]. The
labelled, probe DNA was separated from the unincorporated nucleotides by gel
filtration in order to minimize non-specific binding thus increasing the signal to
noise ratio.
Nitrocellulose (NC) membrane was utilized as the principal solid support
for DNA immobilization in the present study. The chemical nature of the
binding of nucleic acids to NC is unknown, but presumed to be non-covalent
[301]. This assumption implies that the bound nucleic acids may be eluted from
the membrane during hybridization and the subsequent stringent washing
procedures. However, it has been demonstrated that the majority of the
hybridized probe can be removed without eluting significant amounts of the
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immobilized nucleic acids [301, 302]. Nitrocellulose is widely employed in
nucleic acid hybridization experiments because of its relative low cost and
convenience of use. In contrast, the main drawbacks of NC are its fragility after
baking as well as the poor binding capacity for DNA fragments smaller than
200-300 base pairs [301, 303].
Another commonly used solid hybridization support matrix is nylon
membrane. Nucleic acid fragments are covalently bound to it by the reaction
between the primary amino groups on nylon and the thymidine residues of
nucleic acids upon long-wavelength (approximately 254 nm) ultra-violet light
irradiation [304]. In a preliminary study, it was found that the signals obtained
from Southern blot hybridization with cellular DNA samples transferred onto
nylon membranes. (Amersham) were significantly weaker than those obtained
from the same DNA samples blotted onto NC membranes. It was not
determined whether the decreased sensitivity was due to inadequate UV
illumination (5 to 10 minutes with Transilluminator TS-36, UVP, Inc.) or other
unknown factors. Nevertheless, this finding has also been reported in other
studies. The authors claimed that the sensitivity can be reduced as much. as. 25
folds [301] as compared.with that obtained with NC, which also varies with the
nylon membranes of different commercial sources [302].
Nucleic acid hybridization is a useful tool both in research and routine
diagnosis for the detection of viral infection. It does not depend on the active
expression of the viral genomes present in tissue samples, in contrast to
immunological, ultrastructural, and morphological techniques. In addition to
high sensitivity, hybridization assay also suffers less from cross-reactivity and
149
non-specific binding as compared with immunological methods. In the diagnosis
of, HPV infection, owing to the lack of a suitable culture system to propagate
the viruses in vitro, immunological techniques are even not applicable to detect
specific HPV types since only genus-specific antiserum can be prepared by the
immunization with disrupted papillomavirus virions [132].
The stringency of hybridization can be altered by adjusting the
concentration of salt and/or formamide, as well as temperature [301]. As cross-
hybridization among different HPV types is well documented [292], the
hybridization assays in the present study were carried out at 42 0 C with 50%
formamide. This condition has been regarded as a stringent condition for the
detection of individual HPV types [261, 305]. As illustrated in Fig. 4.2, cross-
hybridization was not observed under the hybridization and washing conditions
listed in Table 3.8 indicating that the specificity for the HPV DNA detection is
acceptable. Moreover, attempts to detect HPV DNA in the tissue specimens
other than the four available HPV types under non-stringent hybridization
condition (42° C and 20% formamide) was not successful due to low signal to
noise. ratio. Further studies should be conducted to find out the optimum
condition.
5.2 EBV DNA in Bronchogenic Carcinomas
The association of EBV with a particular disease can be evidenced by the
virus-specific humoral reponse in the patient [306], increased shedding of the
virus in saliva [307], and the presence of EBV DNA in the cells of affected sites
or malignant tissues [308].
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In the Southern blot hybridization analysis of the DNA samples extracted
from bronchogenic carcinomas with a mixture of labelled EBV BarHI -H, -K,
and -W fragments, it was found that 2 out of 28 tumor tissue specimens harbor
EBV DNA. Histologic examination confirmed that they are undifferentiated
squamous cell carcinoma (BC 1T) and poorly differentiated adenocarcinoma
(BC 13T) respectively. In both of the cases, no EBV DNA was detected in the
normal tissue obtained from the same patient indicates that the positive signal
is unlikely due to contaminating blood cells. In BC 1T, the BamHI fragment
of cellular DNA hybridized to EBV BamHI-K fragment was found to be larger
than that of Raji cell DNA (Fig. 4.5). It indicates that variation exists between
the EBV DNAs in the two samples. In literature, variation among the viral
DNAs from different EBV-infected cells as revealed by digestion with Barn HI
and EcoRI has been demonstrated by Heller et al. [45]. The differences among
the DNAs of virus isolates present in different EBV-infected cells may be
important for clinical and epidemiological analysis of EBV infection.
In BC 13T, a single band of about 8.0 kb was detected when the BamHI-
digested DNA was hybridized with a mixed probe of EBV BamHI-H, -K, and
-W fragments (Fig. 4.6). Owing to the unusual size of the hybridizing fragment,
it was suspected* that it might be due to the hybridization of cellular sequences
with the BamHI-K fragment of the EBV genome [296]. Wolf and Seibl claimed
that this region of the viral genome may represent cellular sequences that have
been incorporated into the EBV DNA during the course of evolution [307]. The
experiment was repeated and the blot was hybridized only with the BamHI-W
fragment of EBV genome, the same band was detected indicating that EBV
DNA is present in the tumor specimen (Fig. 4.7). This interesting observation
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awaits explanation through further studies.
In this analysis, no correlation was found between the presence of EBV
DNA and the histologic types of bronchogenic carcinomas in the 28 Hong Kong
Chinese patients. It may be due to the small sample size. However, Lung et al.
as well found no prevalence of EBV in the exfoliated cells harvested from the
bronchial washings of 33 Hong Kong patients with various histologic types of
lung cancer by dot hybridization assay [236]. In contrast, it was illustrated in
this study that the two tumor samples harboring EBV DNA were classified as
poorly differentiated or undifferentiated. This association was also demonstrated
by Begin et al. in a non-keratinizing poorly differentiated carcinoma of the lung
[237], as well as by Desgranges and de-The in undifferentiated small cell
bronchial carcinomas [309] through serological studies. These results might
widen the spectrum of EBV-associated neoplasms to include lesions of the lower
respiratory tract, especially the poorly differentiated and undifferentiated tumors.
As well documented, nasopharyngeal carcinoma is believed to be closely
related to EBV. The viral genome or EBNA is regularly detected in the tumors
which are anaplastic or poorly. differentiated [29, 65, 310, 311, 312], and only
recently in differentiated form of NPC [313]. This coincidence with the finding
in bronchogenic carcinomas indicates that EBV may be predominantly associated
with undifferentiated or poorly differentiated carcinomas. In order to clarify
the role of EBV in the carcinogenesis of tumors with the abovementioned
differentiation, further studies should be conducted on these types of carcinoma.
152
The detection of EBV genome in the tumor cells of NPC indicates that
EBV could enter pharyngeal epithelial cells. In fact, EBV replication in the
epithelial cells of the oropharynx [20], parotid gland [21], and cervical cells [250]
has been reported. To date, it is still not clear how the virus gains access to
these cells. One possibility is that they have EBV receptors. It has been found
that a CR2-like molecule of the B-lineage-specific EBV receptor expressed on
the surface of B lymphocytes is present on the surface of both pharyngeal and
cervical epithelial cells [251, 314]. Another route may be through cell fusion
with EBV genome-containing lymphocytes mediated by an early viral protein [91,
307], which is most probable. to occur in Waldeyer's ring where epithelial cells
and B lymphocytes are in close contact. It is also possible that certain viral
variants exist which can penetrate epithelial cells [29]. Similar to NPC, EBV
may enter bronchial epithelium through these routes.
5.3 HPV DNA in Bronchogenic Carcinomas
In the hybridization assays of the DNA extracted from bronchogenic
carcinomas, no DNA sequence related to HPV types 6, 11, 16, and 18 was
detected in both the tumor and non-tumor tissues. Since hybridization at low
stringency was not performed, it could not be ascertained that other unknown
HPV types are also absent in these tumor specimens. The association of HPV
and lung cancers is not well documented. In the studies that revealed the
presence of HPV in tumor samples through histological examination or nucleic
acid hybridization studies (see Section 2.7 B), the majority are squamous cell
carcinomas. It agrees with the finding in cervical cancer indicating that
papillomaviruses have a specific tropism for squamous epithelial cells. In the
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present study, as there are only 7 tumor tissues in the study group which belong
to this histologic type, it is not surprising that HPV could not be demonstrated.
Syrjanen proposed that HPV infects the bronchial epithelium at the
squamocolumnar junction of the metaplastic squamous epithelium [242]. As
cigarette smoking is capable of inducing such a metaplastic change and the
majority of our cancer patients with squamous cell carcinomas are smokers, it
is worthwhile to examine the association of HPV with this histologic type of
lung cancer.
5.4 EBV DNA in Cervical Cancers
Southern blot analysis of the DNA samples isolated from cervical tissue
specimens revealed no EBV DNA in both the tumor and non-tumor tissues. It
indicates that EBV may not be associated with cervical carcinogenesis in Hong
Kong Chinese patients. However, since the majority of the cases that
demonstrated the presence of EBV in cervical tissues or cervical secretions was
associated with infectious mononucleosis (see Section 2.8), it is possible that the
amount of EBV in the cervical tissue samples is beyond' the detection limit in
this study. Further studies with more sensitive methods such as polymerase
chain reaction (PCR) should be conducted to clarify this point.
5.5 HPV DNA in Cervical Cancers
An etiological role has been proposed for HPV in cervical neoplasia [315].
At least eight types of HPV can infect the lower genital tract but only three
(HPV types 16, 18, 33) are usually associated with malignant changes [107]. It
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is generally believed that cervical cancer develops from precursor lesions with
HPV as one of the trigger factor [198]. Examination of histologically normal
epithelial tissues obtained from control women as well as within 2 to 5 cm of
the tumor revealed the presence of HPV [316, 317, 318]. The same result was
demonstrated in the studies on the normal cervical tissues of Chinese women
in Hong Kong. HPV 16 infections were found to be present in about 6% of the
specimens examined [215, 319]. It indicates that subclinical HPV infection exists.
In this study, no detectable HPV DNA sequence related to HPV types 6, 11, 16,
and 18 was found in the two normal cervical epithelia. However, it does not
exclude the presence of other HPV types. In order to find out the prevalence
of subclinical HPV infections in our population, further study involving more
tissue samples should be conducted.
Southern blot hybridization studies of the DNA from a cervical
intraepithelial neoplasia grade II revealed no HPV DNA related to the four
HPV types tested. This finding is not conclusive due to the small sample size.
In fact, HPV 16 infection can be demonstrated in Hong Kong Chinese patients
with cervical dysplasia [319], although at a lower rate than carcinoma. In
contrast to HPV 16 and HPV 18, studies on premalignant cervical lesions
showed that HPV types 6 and 11 are predominantly associated with genital warts
and low-grade dysplasia, and rarely with carcinomas [320]. Integration of HPV
16 DNA was observed only in high-grade dysplasia and malignant cervical tissue
[321]. Moreover, different transcriptional pattern in precancerous lesions and
invasive carcinomas was suggested to be important in the development of
malignancy [322].
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The analysis of HPV DNA in the 14 squamous cell carcinomas revealed
that 11 (78.6%) tissue specimens harbor DNA sequences related to HPV 16,
while two others (14.3%) related to HPV 18. No association of either HPV
types was demonstrated in the single case of cervical adenocarcinoma.
Moreover, both HPV types 6 and 11 were found to be absent in all the tumor
tissues. However, the presence of other unknown HPV types cannot be ruled
out. The finding obtained in this study indicates that HPV 16 infection is
predominant in the cervical squamous cell carcinomas of Hong Kong Chinese
patients, and possibly plays a role in the neoplastic process. This finding is in
agreement with the result obtained from other studies on cervical cancer in
Hong Kong Chinese women which also showed a prevalence of HPV 16 DNA
in the tumor tissues examined [215, 319, 323]. On a world scale, HPV 16 DNA
was also found to be present in the majority of cervical carcinoma [264, 269],
though the incidence rate varies geographically. The variation may be due to
different cultural background, hygienic conditions and sexual habits. The
incidence of HPV 18 infection in cervical cancer patients is much lower than
HPV 16, this observation is not unique to our population, but common in Asian
women [264, 324, 325]. However, the HPV 18 infection rate is higher in
occidental countries although HPV 16 is still predominantly encountered [270].
HPV 18 appears to be preferentially associated with cervical
adenocarcinoma [326]. As squamous cell carcinoma represents the most
common histologic type of cervical. cancer (about 90-95%) [207], the low
frequency of HPV 18 being detected in cervical tumor tissues may be explained
by the preference of HPV 18 for glandular elements as suggested by Smotkin et
al. [327].
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Hybridization studies showed that no DNA related to HPV types 6 and 11
is present in all the cervical carcinomas. It is in agreement with the studies on
tumor specimens obtained from women in Japan and Taiwan [323]. The
different prevalence of the four HPV types examined in the benign and
malignant lesions of Asian women supports the hypothesis that individual HPV
types infecting the anogenital tract may have different oncogenic potential.
Analysis of the physical state of HPV 16 related DNA sequences it
squamous cell carcinoma specimens revealed the presence of both episomal and
integrated viral DNA sequences, in agreement with several previous studies
[260, 264, 328]. To date, no evidence shows that HPV DNA integrates ai
specific sites in host chromosomes. However, integration usually occurs in
specific manner with a consequent disruption of the El and E2 genes [107, 265]
The disturbed expression of the E2 gene product results in deregulates
expression of the E6 and E7 genes that encode transforming functions [329, 330].
The integration of HPV genome into host cellular DNA has been
suggested to be the prerequisite for malignant conversion in genital tumors
[331]. Two patterns of integration is commonly recognized. The HPV DNA
may be either inserted as head-to-tail tandem repeats or as single copy directly
linked to chromosomal DNA. Both of these patterns are present in the tumor
specimens examined in this study. However, the finding of HPV episomes in
cervical carcinomas, as in some of the tumor tissue samples analyzed here,
suggests that further studies should be conducted to evaluate the role of HPV
integration in cervical carcinogenesis.
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5.6 HPV DNA in CO and Nude Mouse Xenografts
Human papillomaviruses are frequently associated with the cell lines
derived from cervical carcinomas. In contrast to primary tumors, HPV 18 is
predominantly found in cervical cancer cell lines. Moreover, as differ from
carcinoma tissue samples in which the viral genomes may be present in episomal
or integrated forms, nearly all cell lines harbor integrated HPV sequences. The
sole presence of episomal HPV 16 DNA was only demonstrated in a cervical
carcinoma cell line recently established in Taiwan [332].
Southern blot hybridization analysis of the DNA extracted from CO
revealed the presence of integrated, deleted, and rearranged DNA sequences
related to HPV type 16. Alteration of 'the integrated viral genome is also
frequently detected in other cervical cancer cell lines [333, 334]. Moreover,
further studies showed that the HPV DNA exists as repeated units of DNA
sequence integrated into the host chromosome as single copy of the unit or as
head-to-tail tandem repeats at more than one site. The same pattern was found
in the nude mouse xenografts derived from it. However, the viral DNA seems
to have been lost at one of the integration site, implies that rearrangement or
deletion has occurred.
Analysis of the integrated HPV DNA with subgenomic HPV 16 fragments
showed that integration may probably occur with a disruption of the subgenomic
fragment A containing the El and E2 ORFs. Deletion of the early and late
regions has also been demonstrated, in agreement with the finding in other cell
lines [265]. The weak signal detected when the cellular DNA.was probed with
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subgenomic fragments C and F indicates that considerable portions of these
fragments were lost. They contained the E5 ORF responsible for cellular
transformation and plasmid copy number control in BPV-1 as well as the L2
ORF coding for the minor capsid protein (Table 2.2). Subgenomic fragment B
containing the E6 and E7 ORFs probed positively with the BamHI/PstI digested
cellular DNA. Although this subgenomic HPV fragment was found to be altered
in CC3, these two ORFs may also be important in encoding transforming
functions.
In the cervical cancer cell line CC3, there exists complex integration
arrangements together with subgenomic deletions, rearrangements or possibly
sequence reiterations. Further studies, involving molecular cloning and sequence
analysis should be conducted in order to characterize in detail the integrated
HPV genome and the flanking cellular sequence in it. Moreover, the
transcription pattern should also be analyzed in order to clarify the role of HPV
DNA in the tumor cells. Finally, as the viral DNA sequences in CO differ so
much from the prototype HPV 16, the presence of other unknown HPV types
cannot be ruled out.
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CONCLUSION
In this study, examination of the bronchogenic carcinomas of Hong Kong
Chinese patients demonstrated the presence of EBV DNA in two tumor
specimens. One is an undifferentiated squamous cell carcinoma while the other
is a poorly differentiated adenocarcinoma. This finding is in parallel with the
observation in nasopharyngeal carcinoma in which EBV genome is regularly
detected in the undifferentiated and poorly differentiated tumors. Moreover,
no 'EBV DNA was found in the normal lung tissue sample of the same patient
from whom the tumor tissue was obtained. As the EBV DNA present in the
lung tumor specimens was demonstrated to be different from that in Raji cells,
certain EBV variants may be clinically important in the development of lung
cancer. In order to clarify whether EBV is a causative agent or just a passenger
in bronchial carcinogenesis, more studies should be conducted with special focus
on poorly differentiated or undifferentiated tumors.
Analysis of HPV DNA in bronchogenic carcinomas revealed the absence
of DNA sequence related to HPV types 6, 11, 16, and 18 in all the tumor and
non-tumor tissue specimens. However, the presence of other unknown HPV
types cannot be ruled out. As several studies have reported the detection of
HPV infection preferentially in squamous cell bronchial carcinomas, further
studies should be conducted to investigate the association of HPV and lung
cancer development in our population, especially on the squamous histologic
type.
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Southern blot hybridization analysis of cervical tissue specimens revealed
no EBV in all the tumor tissues, as well as in dysplasia and normal epithelial
cells. On the contrary, HPV DNA was demonstrated in the majority of cervical
squamous cell carcinomas, in which HPV 16 is predominantly encountered. This
prevalence indicates that cervical squamous cell cancer of Hong Kong Chinese
women is closely associated with HPV 16. Moreover, both episomal and
integrated form of viral DNA were found in the tissue specimens. It implies
that integration into host cellular DNA sequence is not mandatory in cervical
carcinogenesis in the women of our population. Studies should be conducted
to investigate the presence of HPV DNA in normal epithelial tissues, dysplasias
of various grades of abnormality, as well as carcinomas, so as to obtain more
knowledge about its association with the spectrum of cervical neoplastic changes.
The finding is useful for designing screening programs which aim at the early
discovery of curable lesions.
The cervical cancer cell line CC3 was derived from a well differentiated
squamous cell carcinoma taken from a Hong Kong Chinese women. Southern
blot hybridization analysis revealed that CO, as well as the nude mouse
xenografts developed from it, harbor integrated, deleted, and rearranged HPV
DNA related to HPV type 16. The viral sequence appears to be integrated into
the host cell DNA somewhere within the region containing the El and E2 ORFs.
Deletion of early and late regions was found. Deletion or rearrangement of the
HPV DNA was also demonstrated when the cell line was heterotransplanted
into nude mice. Further studies, involving molecular cloning and the analysis
of transcription pattern, will be helpful in determining the significance of HPV
DNA in these specimens.
161
In order to prove that EBV and HPV are involved in carcinogenesis,
studies should be conducted in order to satisfy certain criteria for oncogenic
viruses as summarized by Crawford in 1986 [335]:
1. The virus should be associated with the tumor in the forms of virus
particles, DNA or RNA, as well as higher titres of antiviral antibodies in
the patient as compared with control.
2. The virus should be able to induce tumor in animals.
3. The virus should be capable of transforming normal cells in vitro.
When all or most of the above criteria are satisfied, there is good
circumstantial evidence to support the virus tumor association in question.
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